Advanced
Search

Special Article

Shattuck Lecture

Neurodegenerative Diseases and Prions

Stanley B. Prusiner, M.D.

N Engl J Med 2001; 344:1516-1526May 17, 2001DOI: 10.1056/NEJM200105173442006

Article

Twenty-five years ago, little was known about the causes of neurodegenerative diseases. Now, however, it is clear that they result from abnormalities in the processing of proteins. In each of these diseases, defective processing causes the accumulation of one or more specific neuronal proteins.

Of all the laboratory research on neurodegenerative diseases, the studies that led to the discovery of prions have yielded the most unexpected findings. The idea that a protein can act as an infectious pathogen and cause degeneration of the central nervous system was accepted only after a long and arduous battle.1 The concept of prions not only has provided an explanation of how a disease can be both infectious and genetic, but has also revealed hitherto unknown kinds of neurologic diseases. This review presents a unifying concept of degenerative brain diseases, based on what we have learned about prions.2

Alzheimer's disease is the most common neurodegenerative disorder (Table 1Table 1Prevalence of Neurodegenerative Diseases in the United States in 2000.). In the United States, approximately 4 million people have Alzheimer's disease, and approximately 1 million have Parkinson's disease.3-5 Much less common are amyotrophic lateral sclerosis, frontotemporal dementia, prion diseases, Huntington's disease, and spinocerebellar ataxias.

With the increase in life expectancy, there has been concern about the incidence of Alzheimer's and Parkinson's diseases. Among persons who are 60 years old, the prevalence of Alzheimer's disease is approximately 1 in 10,000, but among those who are 85 years old, it is greater than 1 in 3.6 These data suggest that by 2025, there will be more than 10 million cases of Alzheimer's disease in the United States, and by 2050, the number will approach 20 million.4 The annual cost associated with Alzheimer's disease in the United States is estimated at $200 billion. Age is also the most important risk factor for Parkinson's disease. Nearly 50 percent of persons who are 85 years old also have at least one symptom or sign of parkinsonism.7

Virtually all neurodegenerative disorders involve abnormal processing of neuronal proteins. The aberrant mechanism can entail a misfolding of proteins, altered post-translational modification of newly synthesized proteins, abnormal proteolytic cleavage, anomalous gene splicing, improper expression, or diminished clearance of degraded protein. Misprocessed proteins often accumulate because the cellular mechanisms for removing them are ineffective. The particular protein that is improperly processed determines the malfunction of distinct sets of neurons and thus the clinical manifestations of the disease.

Prions

Prions are infectious proteins. In mammals, prions reproduce by recruiting normal cellular prion protein (PrPC) and stimulating its conversion to the disease-causing (scrapie) isoform (PrPSc). A major feature that distinguishes prions from viruses is that PrPSc is encoded by a chromosomal gene.8 Limited proteolysis of PrPSc produces a smaller, protease-resistant molecule of approximately 142 amino acids, designated PrP 27–30, which polymerizes into amyloid.9

The polypeptide chains of PrPC and PrPSc are identical in composition but differ in their three-dimensional, folded structures (conformations). PrPC is rich in α-helixes (spiral-like formations of amino acids) and has little β-sheet (flattened strands of amino acids), whereas PrPSc is less rich in α-helixes and has much more β-sheet.10 There is evidence that PrPC has three α-helixes and two short β-strands; in contrast, a plausible model suggests that PrPSc may have only two α-helixes and more β-strands (Figure 1Figure 1Structures of Prion Protein (PrP) Isoforms.).11,12 This structural transition from α-helixes to β-sheet in PrP is the fundamental event underlying prion diseases.

Four new concepts have emerged from studies of prions. First, prions are the only known example of infectious pathogens that are devoid of nucleic acid. All other infectious agents possess genomes composed of either RNA or DNA that direct the synthesis of their progeny. Second, prion diseases may be manifested as infectious, genetic, or sporadic disorders. No other group of illnesses with a single cause has such a wide spectrum of clinical manifestations. Third, prion diseases result from the accumulation of PrPSc, which has a substantially different conformation from that of its precursor, PrPC. Fourth, PrPSc can have a variety of conformations, each of which seems to be associated with a specific disease. How a particular conformation of PrPSc is imparted to PrPC during replication in order to produce a nascent PrPSc with the same conformation is unknown. The factors that determine the site in the central nervous system where a particular PrPSc is deposited are also not known.

Prion Diseases

Prion diseases have a broad spectrum of clinical manifestations, including dementia, ataxia, insomnia, paraplegia, paresthesias, and deviant behavior.13 Neuropathological findings range from an absence of atrophy to widespread atrophy, from minimal to widespread neuronal loss, from sparse to widespread vacuolation or spongiform changes, from mild to severe reactive astrocytic gliosis, and from an absence of PrP amyloid plaques to an abundance of plaques.14 None of these findings except the presence of PrP amyloid plaques is unequivocally diagnostic of a prion disease.

The sporadic form of Creutzfeldt–Jakob disease, which is typically manifested as dementia and myoclonus, accounts for approximately 85 percent of all cases of prion disease in humans, whereas infectious and inherited prion diseases account for the rest. Familial Creutzfeldt–Jakob disease, Gerstmann–Sträussler–Scheinker disease, and fatal familial insomnia are all dominantly inherited prion diseases caused by mutations in the prion protein gene (PRNP) (Table 2Table 2Pathogenetic Features of Prion Diseases.).15-19 Experiments that showed transmission of these diseases by filtrates of brain from familial cases20,21 were wrongly attributed to a virus. There is no Creutzfeldt–Jakob disease virus, and familial prion diseases are caused by mutations in PRNP. 22

Epidemiologic Features

Prions cause Creutzfeldt–Jakob disease in humans throughout the world. The incidence of sporadic Creutzfeldt–Jakob disease is approximately 1 case per 1 million population,23 but among persons between the ages of 60 and 74 years, the incidence is nearly 5 per 1 million.24 Cases in patients as young as 17 years and as old as 83 have been recorded.23,25 Creutzfeldt–Jakob disease is relentlessly progressive and usually causes death within a year after its onset. Each geographic cluster of cases of prion disease was initially thought to be a manifestation of viral communicability,26 but each was later shown to be due to a PRNP gene mutation except for new variant Creutzfeldt–Jakob disease.

Neuropathological Features

There are often no recognizable gross abnormalities in the brains of patients with Creutzfeldt–Jakob disease. Patients who survive for several years have variable degrees of cerebral atrophy. The microscopical features of Creutzfeldt–Jakob disease are spongiform degeneration and astrogliosis (Figure 2AFigure 2Neuropathological Features of Prion Diseases in Humans. and Figure 2B).27

Amyloid plaques occur in approximately 10 percent of cases of Creutzfeldt–Jakob disease. These plaques are positive for antibodies against PrPSc on immunohistochemical staining.28,29 The amyloid plaques in patients with Gerstmann–Sträussler–Scheinker disease consist of a dense core of amyloid surrounded by smaller globules of amyloid (Figure 2). A characteristic feature of new variant Creutzfeldt–Jakob disease is the presence of “florid plaques” composed of a core of PrPSc amyloid surrounded by vacuoles (Figure 2E and Figure 2F).

Strains of Prions

The existence of prion strains raises the question of how heritable biologic information can be encrypted in a molecule other than nucleic acid.30-32 Strains of prions have been defined by the rapidity with which they cause central nervous system disease and by the distribution of neuronal vacuolation.30 Patterns of PrPSc deposition have also been used to characterize these strains.33,34 There is mounting evidence that the diversity of prions is enciphered in the conformation of the PrPSc protein.35-39 Studies involving the transmission of fatal familial insomnia and familial Creutzfeldt–Jakob disease to mice expressing a chimeric human–mouse PrP transgene have shown that the tertiary and quaternary structure of PrPSc contains strain-specific information.37 Studies of patients with fatal sporadic insomnia have extended these findings,40 making it clear that PrPSc acts as a template for the conversion of PrPC into nascent PrPSc.

Sporadic, Genetic, and Infectious Forms of Prion Disease

Sporadic prion diseases might be initiated by a somatic mutation and in this respect might develop in a manner similar to prion diseases caused by germ-line mutations. In this situation, the mutant PrPSc must be capable of recruiting wild-type PrPC, a process that may occur with some mutations but is unlikely with others.41 Alternatively, the activation barrier separating wild-type PrPC from PrPSc may be crossed on rare occasions in the context of a large population of people.42 Twenty mutations in the human PRNP gene have been found to segregate with inherited prion diseases.43 Missense mutations and expansions in the octapeptide-repeat region of the gene cause familial prion diseases.15-19

Although infectious prion diseases constitute less than 1 percent of all cases of prion disease, the circumstances surrounding the transmission of these infectious illnesses are often dramatic (Table 2). Ritualistic cannibalism has resulted in the transmission of kuru among the Fore people of New Guinea, industrial cannibalism has been responsible for bovine spongiform encephalopathy (BSE), or “mad cow disease,” in Europe, and an increasing number of patients have contracted new variant Creutzfeldt–Jakob disease from prion-tainted beef products.13

The restricted geographic and temporal distribution of cases of new variant Creutzfeldt–Jakob disease raises the possibility that BSE prions have been transmitted to humans. Although over 100 cases of new variant Creutzfeldt–Jakob disease have been recorded,44,45 no dietary habits distinguish patients with this disease from apparently healthy persons. Moreover, it is unclear why teenagers and young adults seem to be particularly susceptible to the disease. These cases may mark the start of an epidemic of prion disease in Great Britain like those of BSE and kuru, or the number of cases of new variant Creutzfeldt–Jakob disease may remain small, as with iatrogenic Creutzfeldt–Jakob disease caused by cadaveric human growth hormone.46

The most compelling evidence that new variant Creutzfeldt–Jakob disease is caused by BSE prions comes from studies of mice expressing the bovine PrP transgene.47 The incubation times, neuropathological features, and patterns of PrPSc deposition in these transgenic mice are the same whether the inoculate originated from the brains of cattle with BSE or from humans with new variant Creutzfeldt–Jakob disease.47 The origin of BSE is still obscure, although epidemiologic studies indicate that BSE probably arose from a single point source in the southwest of England in the 1970s.48 It probably originated from a rare case of prion disease in either sheep (Scott M, Prusiner SB: unpublished data) or cattle.48 Once established, the disease was spread in cattle by ingestion of prion-contaminated meat and bone meal.

The accidental transmission of Creutzfeldt–Jakob disease to humans appears to have occurred with corneal transplantation49 and use of contaminated electroencephalographic electrodes.50 The same improperly decontaminated electrodes that had caused Creutzfeldt–Jakob disease in two young patients with intractable epilepsy were found to cause Creutzfeldt–Jakob disease in a chimpanzee 18 months after their implantation in the animal.51 More than 70 cases of Creutzfeldt–Jakob disease associated with the implantation of dura mater grafts have been recorded.52 One case occurred after the repair of a perforated eardrum with a pericardial graft.53 Prion-contaminated human growth hormone preparations derived from human pituitary tissue have caused fatal cerebellar disorders with dementia in more than 120 patients ranging in age from 10 to 41 years.13,54,55 Four cases of Creutzfeldt–Jakob disease have occurred in women who received human pituitary gonadotropin.56

Polymorphisms influence the susceptibility to sporadic, inherited, and infectious forms of prion disease. Dominant negative alleles in approximately 12 percent of the Japanese population57 encode for lysine at position 219 and interfere with the conversion of wild-type PrPC into PrPSc.58,59 Dominant negative inhibition of prion replication has also been found in sheep, with a substitution of the basic residue arginine at position 171.60,61

Other Neurodegenerative Diseases

Like cases of the prion diseases, most cases of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and frontotemporal dementia are sporadic; 10 percent or less are inherited. Although age is the most important risk factor in all these sporadic forms of disease, the factors that initiate neurodegeneration remain unknown. In the prion diseases, the initial formation of PrPSc leads to an exponential increase in the protein, which can be readily transmitted to another host. In the other neurodegenerative diseases, the events that lead to the production of aberrantly processed proteins, as well as the driving forces that sustain their accumulation, are unknown. It is important to stress that in contrast to the prion diseases, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and frontotemporal dementia are not infectious and have not been transmitted to laboratory animals.

Alzheimer's Disease

Aβ-amyloid plaques and neurofibrillary tangles are found in both sporadic and inherited forms of Alzheimer's disease (Table 3Table 3Protein Deposition in Neurodegenerative Diseases.). Like familial prion diseases, familial Alzheimer's disease has an autosomal dominant pattern of inheritance. Familial Alzheimer's disease can be caused by a mutation in the gene for amyloid precursor protein (APP), presenilin 1, or presenilin 2 (Table 4Table 4Mutant Genes in Familial Neurodegenerative Diseases.).62 Cleavage of amyloid precursor protein at residue 671 by β-secretase and at either residue 711 or residue 713 by γ-secretase produces Aβ(1–40) and Aβ(1–42), respectively. Aβ(1–42) forms amyloid fibrils readily and is thought to cause central nervous system dysfunction before it is deposited in plaques.63-65 Presenilin 1 and presenilin 2 may form complexes with at least one other protein, nicastrin, a transmembrane neuronal glycoprotein, and these complexes may contribute to the production of Aβ(1–42).66

The age of onset of both sporadic and familial forms of Alzheimer's disease is modulated by allelic variants of apolipoprotein E.67 Three alternative allelic products of apolipoprotein E, denoted ε2, ε3, and ε4, differ at amino acid residues 112 and 158. In many persons with two ε4 alleles, Alzheimer's disease develops at least a decade before it does in those with two copies of ε2, and ε3 is associated with an onset of disease at an intermediate age.68

Frontotemporal Dementia and Pick's Disease

Mutations in the tau gene, which codes for tau, a protein associated with microtubules, cause inherited forms of frontotemporal dementia and Pick's disease.69-71 As with Alzheimer's disease, about 90 percent of cases of frontotemporal dementia are sporadic, and the rest are familial. Straight filaments composed of hyperphosphorylated mutant tau have been found in the brains of patients with familial frontotemporal dementia (Table 3).72 In some cases, neurofibrillary tangles composed of paired helical filaments have been found; the formation of these filaments seems to depend on the specific mutation and on the specific isoform of the protein (Table 4).73 In sporadic cases of frontotemporal dementia, aggregates of tau are uncommon. Approximately 15 percent of patients with frontotemporal dementia have Pick bodies,74 which are intracellular collections of partially degraded (ubiquinated) tau fibrils in the brain.75 As with frontotemporal dementia, most cases of Pick's disease are sporadic. Other disorders caused by the misprocessing of tau include progressive supranuclear palsy, progressive subcortical gliosis, and corticobasal degeneration.73,75-77

Parkinson's Disease

Most cases of Parkinson's disease are sporadic,78,79 but both sporadic and familial forms of the disease are characterized by protein deposits in the central nervous system. Mutations in the gene for α-synuclein have been found in patients with familial Parkinson's disease.80 In both sporadic and familial cases, antibodies to α-synuclein, a presynaptic intracellular protein, stain Lewy bodies in neurons of the substantia nigra.81 Whereas the inheritance of Parkinson's disease due to mutations in the α-synuclein gene is autosomal dominant, a childhood form of the disease due to mutations in the gene for ubiquitin–protein ligase (parkin) is a recessive disorder (Table 4).82 Parkin seems to promote the degradation of certain neuronal proteins, and selective nitration of α-synuclein has been observed in Lewy bodies.83

Parkinson's disease in older persons is associated with a high incidence of dementia.84 At autopsy, the brains of such patients often have the neuropathological hallmarks of both Alzheimer's disease and Parkinson's disease. Immunohistochemical studies showing the presence of α-synuclein in cortical Lewy bodies have helped resolve the conundrum of how a patient could have insufficient numbers of plaques and neurofibrillary tangles for the diagnosis of Alzheimer's disease but still have dementia. The presence of these α-synuclein deposits, alone or in combination with changes that are characteristic of Alzheimer's disease, may be the second most common form of neurodegeneration, accounting for 20 to 30 percent of cases of dementia among persons over the age of 60 years.85,86 A small number of younger persons with Parkinson's disease also have dementia due to diffuse Lewy body disease.87

Amyotrophic Lateral Sclerosis

Although most cases of amyotrophic lateral sclerosis are sporadic, familial cases have been identified.88-90 In approximately 20 percent of familial cases of amyotrophic lateral sclerosis, there are mutations in the gene for cytoplasmic superoxide dismutase type 1 (SOD1) (Table 4).91 Moreover, deposits of SOD1 in the central nervous system have been found in both sporadic and familial cases of amyotrophic lateral sclerosis.92 Although in some cases abnormal collections of neurofilaments have been seen in degenerating motor neurons, no familial cases have been shown to be due to mutations in neurofilament genes.92

Huntington's Disease and Spinocerebellar Ataxias

Unlike Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis, and the prion diseases, which in most cases are sporadic, all cases of Huntington's disease and of spinocerebellar ataxia are caused by expanded polyglutamine repeats (Table 4).93-95 But these diseases are similar to the inherited forms of Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis, and the prion diseases in that they are usually manifested as neurologic deficits in adulthood, even though the expression of the mutant gene products in the central nervous system begins early in life. Childhood forms of Huntington's disease and spinocerebellar ataxia are known to be due to large expansions of the causative triplet repeats.94,96,97

Transgenic Mouse Models

Although virtually every facet of the human and animal prion diseases has been reproduced in transgenic mice, attempts to develop transgenic models for the other neurodegenerative diseases have proved more difficult. Despite the lack of perfect transgenic models for Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementias, Huntington's disease, and the spinocerebellar ataxias, many aspects of these human disorders have been reproduced. Mice expressing transgenes carrying mutations found in the inherited forms of these neurodegenerative diseases develop disorders with many of the neuropathological features that characterize the corresponding human illnesses (Table 3 and Table 4).

Diagnostic Tests

There is an urgent need for a rapid, antemortem test for prions in humans and livestock. A highly sensitive quantitative immunoassay has been developed on the basis of antigens that are exposed in PrPC but buried in PrPSc. Unlike earlier immunoassays for PrPSc, this conformation-dependent immunoassay does not require limited proteolysis to hydrolyze PrPC before the protease-resistant core of PrPSc (PrP 27–30) is measured.38 This assay has been used to identify a new form of PrPSc, which is protease-sensitive (sPrPSc).

A diagnostic test would be valuable for distinguishing between early Alzheimer's disease and depression in older persons, since both disorders are so common. In Alzheimer's disease, frontotemporal dementia, Parkinson's disease, and the prion diseases, computed tomography or magnetic resonance imaging may show normal findings or cortical atrophy. In patients with Alzheimer's disease, widespread atrophy with enlarged ventricles is often seen, especially late in the disease, but this finding is not diagnostic. Many elderly persons with normal cognition have similar radiographic findings.98,99 Although many patients with Creutzfeldt–Jakob disease have elevated levels of protein 14-3-3 in cerebrospinal fluid, this finding is not specific for the diagnosis.100,101 Attempts to measure Aβ(1–40) in blood and urine as diagnostic tests have been unrewarding,102 but the use of fluorescence correlation spectroscopy to measure Aβ(1–40) in cerebrospinal fluid may provide a reliable diagnostic test for Alzheimer's disease.103

Whereas electroencephalographic studies are not useful for the diagnosis of Alzheimer's disease, frontotemporal dementia, or Parkinson's disease, they are often useful for the diagnosis of Creutzfeldt–Jakob disease. Repetitive, high-voltage, triphasic and polyphasic sharp discharges are seen in most advanced cases of Creutzfeldt–Jakob disease, but their presence is often transient.25,101,104,105 As the disease progresses, normal background rhythms become fragmentary and slower.

Hashimoto's thyroiditis should always be considered in the differential diagnosis of Creutzfeldt–Jakob disease,106 since the former disorder is a treatable autoimmune disease whereas Creutzfeldt–Jakob disease is not. The clinical and neuropathological findings in these two disorders can be quite similar, raising the possibility that protein misprocessing underlies both degenerative and autoimmune diseases.

Prevention and Treatment

With the exception of levodopa, which ameliorates the symptoms of Parkinson's disease but does not halt the underlying degeneration, there are no effective therapies for neurodegenerative diseases. The history of successful attempts to prevent or reverse protein misprocessing is extremely limited.107 Developing new drugs directed to specific regions of the central nervous system will be challenging.

Preventing Abnormal Processing of Proteins and Enhancing Their Clearance

Structure-based drug design based on dominant negative inhibition of prion formation has resulted in the development of several compounds.108 However, the task of exchanging polypeptide scaffolds for small heterocyclic structures without the loss of biologic activity remains difficult. Whether this approach to preventing the aberrant processing of proteins will lead to the development of new treatments for Alzheimer's and Parkinson's diseases, as well as other neurodegenerative disorders, remains to be established.

Several compounds can eliminate prions from cultured cells. A class of compounds known as “dendrimers” seems particularly effective in this regard.109 Some drugs delay the onset of disease in animals that have been inoculated with prions if the drugs are given around the time of the inoculation.110 A novel approach to treating Alzheimer's disease has been developed in transgenic mice that overexpress a mutant APP gene. Immunization of these mice with the Aβ peptide or injection of antibodies to Aβ reduces plaque formation.111 Whether this approach will prove fruitful in patients is unknown.

Replacement Therapy

Because the neurodegeneration in Parkinson's disease is confined largely to the substantia nigra, especially early in the disease process, replacement therapy with levodopa has proved useful; in many patients, however, the disease eventually becomes refractory to levodopa.112 Similar approaches to the treatment of Alzheimer's disease have been disappointing, primarily because the disease process is so widespread. Similarly, the widespread neuropathological changes in amyotrophic lateral sclerosis, frontotemporal dementia, and prion diseases make it unlikely that replacement therapy will be successful.

Speculation on the Spectrum of Degenerative Diseases

It is tempting to speculate that abnormal processing of neuronal proteins also occurs in other diseases of the central nervous system, such as schizophrenia, bipolar disorders, autism, and narcolepsy.113 Most cases of these diseases are sporadic, but a substantial minority appear to be familial. The absence of neuropathological changes in these conditions has impeded phenotypic analysis. In a group of patients with inherited frontotemporal dementia who have a mutation in the tau gene, alcoholism and Parkinson's disease are prominent features.114

Whether multiple sclerosis is also the result of defective processing of brain proteins is unknown.115 The immune system features prominently in the pathogenesis of multiple sclerosis, and it is often argued that this disease is a T-cell–mediated, autoimmune disorder. Antibody-mediated demyelination has been found in some cases of multiple sclerosis,116 and in others, degeneration of oligodendrocytes has been observed, with little or no evidence of immune-mediated damage.117 Perhaps ulcerative colitis, Crohn's disease, rheumatoid arthritis, type 1 diabetes mellitus, and systemic lupus erythematosus ought to be considered disorders of protein processing in which misfolded proteins evoke an autoimmune response.

The systemic amyloidoses share important features with the neurodegenerative diseases. In primary amyloidosis, immunoglobulin light chains form amyloid deposits that can cause cardiomyopathy, renal failure, and polyneuropathy.118 In response to chronic inflammatory diseases, the serum amyloid A protein is cleaved and forms the amyloid A protein, which is deposited as fibrils in the kidney, liver, and spleen. The most common form of systemic hereditary amyloidosis is caused by the deposition of mutant transthyretin. Also noteworthy are amylin deposits in the β-islet cells of patients with type 2 diabetes mellitus. These deposits contain amyloid fibrils that are composed of the amylin protein.

The Future

As life expectancy continues to increase, the burden of degenerative diseases is growing. Developing effective means of preventing these disorders and of treating them when they do occur is a paramount challenge. The problems caused by Alzheimer's disease and Parkinson's disease are already so great that if the prevalence of these maladies continues to increase in accordance with the changing demographic characteristics of the world population, they will bankrupt both developed and developing countries over the next 50 years. It is remarkable to think that by the year 2025, more than 65 percent of persons over the age of 65 years will be living in countries that are now designated as developing countries.119 Unless effective methods of prevention and treatment are developed, this enormous population of people will be subjected to the same risks of Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders as are older persons currently living in the most affluent countries.

Over the past two decades, remarkable progress has been made in elucidating the causes of neurodegenerative diseases, and the time has come to intensify the search for drug targets and for compounds that interrupt the disease processes. Drugs that block the mishandling of a particular protein may be most effective for certain disorders; for others, drugs that enhance the clearance of an aberrant protein or fragment may prove most useful. Regardless of the therapeutic approach, accurate, early detection of neurodegeneration will be extremely important so that drugs can be given before substantial damage to the central nervous system has occurred. However, the enormity of these tasks — developing useful diagnostic tests and discovering effective therapies — should not be underestimated.

Presented as the 110th Shattuck Lecture to the Annual Meeting of the Massachusetts Medical Society, Boston, May 20, 2000.

Supported by grants from the National Institutes of Health (NS14069, AG02132, and AG10770), the American Health Assistance Foundation, and the Leila and Harold Mathers Foundation.

I am indebted to Drs. Fred Cohen, Stephen DeArmond, Kirk Wilhemsen, Robert Edwards, Warren Olanow, Steve Finkbiener, and Steve Hauser for their valuable comments and suggestions; to Dr. Fred Cohen for preparation of the PrP structural illustrations; and to Dr. Stephen DeArmond for preparation of the photomicrographs.

Source Information

From the Institute for Neurodegenerative Diseases and the Departments of Neurology and of Biochemistry and Biophysics, University of California, San Francisco.

Address reprint requests to Dr. Prusiner at the Institute for Neurodegenerative Diseases, Box 0518, University of California, San Francisco, CA 94143-0518.

References

References

  1. 1

    Prusiner SB. Development of the prion concept. In: Prusiner SB, ed. Prion biology and diseases. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press, 1999:67-112.

  2. 2

    Prusiner SB. Some speculations about prions, amyloid, and Alzheimer's disease. N Engl J Med 1984;310:661-663
    Full Text | Web of Science | Medline

  3. 3

    Lilienfeld DE. An epidemiological overview of amyotrophic lateral sclerosis, Parkinson's disease, and dementia of the Alzheimer type. In: Calne DB, ed. Neurodegenerative diseases. Philadelphia: W.B. Saunders, 1994:399-425.

  4. 4

    Kawas CH, Katzman R. Epidemiology of dementia and Alzheimer disease. In: Terry RD, Katzman R, Bick KL, Sisodia SS, eds. Alzheimer disease. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 1999:95-116.

  5. 5

    Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neuroepidemiology 1996;14:317-335

  6. 6

    Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989;10:2551-2556
    CrossRef | Web of Science

  7. 7

    Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996;334:71-76
    Free Full Text | Web of Science | Medline

  8. 8

    Prusiner SB. Prions. Proc Natl Acad Sci U S A 1998;95:13363-13383
    CrossRef | Web of Science | Medline

  9. 9

    McKinley MP, Meyer RK, Kenaga L, et al. Scrapie prion rod formation in vitro requires both detergent extraction and limited proteolysis. J Virol 1991;65:1340-1351
    Web of Science | Medline

  10. 10

    Pan K-M, Baldwin M, Nguyen J, et al. Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S A 1993;90:10962-10966
    CrossRef | Web of Science | Medline

  11. 11

    Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Wuthrich K. NMR structure of the mouse prion protein domain PrP(121-231). Nature 1996;382:180-182
    CrossRef | Web of Science | Medline

  12. 12

    Liu H, Farr-Jones S, Ulyanov NB, et al. Solution structure of Syrian hamster prion protein rPrP(90-231). Biochemistry 1999;38:5362-5377
    CrossRef | Web of Science | Medline

  13. 13

    Will RG, Alpers MP, Dormont D, Schonberger LB, Tateishi J. Infectious and sporadic prion diseases. In: Prusiner SB, ed. Prion biology and diseases. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press, 1999:465-507.

  14. 14

    DeArmond SJ, Prusiner SB. Prion diseases. In: Graham DI, Lantos PL, eds. Greenfield's neuropathology. 6th ed. London: Arnold, 1997:235-80.

  15. 15

    Hsiao K, Baker HF, Crow TJ, et al. Linkage of a prion protein missense variant to Gerstmann-Sträussler syndrome. Nature 1989;338:342-345
    CrossRef | Web of Science | Medline

  16. 16

    Dlouhy SR, Hsiao K, Farlow MR, et al. Linkage of the Indiana kindred of Gerstmann-Sträussler-Scheinker disease to the prion protein gene. Nat Genet 1992;1:64-67
    CrossRef | Web of Science | Medline

  17. 17

    Petersen RB, Tabaton M, Berg L, et al. Analysis of the prion protein gene in thalamic dementia. Neurology 1992;42:1859-1863
    Web of Science | Medline

  18. 18

    Poulter M, Baker HF, Frith CD, et al. Inherited prion disease with 144 base pair gene insertion. 1. Genealogical and molecular studies. Brain 1992;115:675-685
    CrossRef | Web of Science | Medline

  19. 19

    Gabizon R, Rosenmann H, Meiner Z, et al. Mutation and polymorphism of the prion protein gene in Libyan Jews with Creutzfeldt-Jakob disease (CJD). Am J Hum Genet 1993;53:828-835
    Web of Science | Medline

  20. 20

    Roos R, Gajdusek DC, Gibbs CJ Jr. The clinical characteristics of transmissible Creutzfeldt-Jakob disease. Brain 1973;96:1-20
    CrossRef | Web of Science | Medline

  21. 21

    Masters CL, Gajdusek DC, Gibbs CJ Jr. Creutzfeldt-Jakob disease virus isolations from the Gerstmann-Sträussler syndrome with an analysis of the various forms of amyloid plaque deposition in the virus-induced spongiform encephalopathies. Brain 1981;104:559-588
    CrossRef | Web of Science | Medline

  22. 22

    Hsiao K, Doh-ura K, Kitamoto T, Tateishi J, Prusiner SB. A prion protein amino acid substitution in ataxic Gerstmann-Sträussler syndrome. Ann Neurol 1989;26:137-137 abstract.
    Web of Science

  23. 23

    Masters CL, Harris JO, Gajdusek DC, Gibbs CJ, Bernoulli C, Asher DM. Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol 1979;5:177-188
    CrossRef | Web of Science | Medline

  24. 24

    Holman RC, Khan AS, Belay ED, Schonberger LB. Creutzfeldt-Jakob disease in the United States, 1979-1994: using national mortality data to assess the possible occurrence of variant cases. Emerg Infect Dis 1996;2:333-337
    CrossRef | Web of Science | Medline

  25. 25

    Cathala F, Baron H. Clinical aspects of Creutzfeldt-Jakob disease. In: Prusiner SB, McKinley MP, eds. Prions — novel infectious pathogens causing scrapie and Creutzfeldt-Jakob disease. Orlando, Fla.: Academic Press, 1987:467-509.

  26. 26

    Kahana E, Alter M, Braham J, Sofer D. Creutzfeldt-Jakob disease: focus among Libyan Jews in Israel. Science 1974;183:90-91
    CrossRef | Web of Science | Medline

  27. 27

    DeArmond SJ, Ironside JW. Neuropathology of prion diseases. In: Prusiner SB, ed. Prion biology and diseases. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press, 1999:585-652.

  28. 28

    Bendheim PE, Barry RA, DeArmond SJ, Stites DP, Prusiner SB. Antibodies to a scrapie prion protein. Nature 1984;310:418-421
    CrossRef | Web of Science | Medline

  29. 29

    DeArmond SJ, McKinley MP, Barry RA, Braunfeld MB, McColloch JR, Prusiner SB. Identification of prion amyloid filaments in scrapie-infected brain. Cell 1985;41:221-235
    CrossRef | Web of Science | Medline

  30. 30

    Dickinson AG, Meikle VMH, Fraser H. Identification of a gene which controls the incubation period of some strains of scrapie agent in mice. J Comp Pathol 1968;78:293-299
    CrossRef | Web of Science | Medline

  31. 31

    Bruce ME, Dickinson AG. Biological evidence that scrapie agent has an independent genome. J Gen Virol 1987;68:79-89
    CrossRef | Web of Science | Medline

  32. 32

    Ridley RM, Baker HF. To what extent is strain variation evidence for an independent genome in the agent of the transmissible spongiform encephalopathies? Neurodegeneration 1996;5:219-231
    CrossRef | Medline

  33. 33

    DeArmond SJ, Mobley WC, DeMott DL, Barry RA, Beckstead JH, Prusiner SB. Changes in the localization of brain prion proteins during scrapie infection. Neurology 1987;37:1271-1280[Erratum, Neurology 1987;37:1770.]
    Web of Science | Medline

  34. 34

    Bruce ME, McBride PA, Farquhar CF. Precise targeting of the pathology of the sialoglycoprotein, PrP, and vacuolar degeneration in mouse scrapie. Neurosci Lett 1989;102:1-6
    CrossRef | Web of Science | Medline

  35. 35

    Prusiner SB. Molecular biology of prion diseases. Science 1991;252:1515-1522
    CrossRef | Web of Science | Medline

  36. 36

    Bessen RA, Marsh RF. Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. J Virol 1994;68:7859-7868
    Web of Science | Medline

  37. 37

    Telling GC, Parchi P, DeArmond SJ, et al. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 1996;274:2079-2082
    CrossRef | Web of Science | Medline

  38. 38

    Scott MR, Groth D, Tatzelt J, et al. Propagation of prion strains through specific conformers of the prion protein. J Virol 1997;71:9032-9044
    Web of Science | Medline

  39. 39

    Safar J, Wille H, Itri V, et al. Eight prion strains have PrPSc molecules with different conformations. Nat Med 1998;4:1157-1165
    CrossRef | Web of Science | Medline

  40. 40

    Mastrianni JA, Nixon R, Layzer R, et al. Prion protein conformation in a patient with sporadic fatal insomnia. N Engl J Med 1999;340:1630-1638
    Free Full Text | Web of Science | Medline

  41. 41

    Telling GC, Scott M, Mastrianni J, et al. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 1995;83:79-90
    CrossRef | Web of Science | Medline

  42. 42

    Cohen FE, Prusiner SB. Pathologic conformations of prion proteins. Annu Rev Biochem 1998;67:793-819
    CrossRef | Web of Science | Medline

  43. 43

    Gambetti P, Petersen RB, Parchi P, et al. Inherited prion diseases. In: Prusiner SB, ed. Prion biology and diseases. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press, 1999:509-83.

  44. 44

    Will RG, Cousens SN, Farrington CP, Smith PG, Knight RSG, Ironside JW. Deaths from variant Creutzfeldt-Jakob disease. Lancet 1999;353:979-979
    CrossRef | Web of Science | Medline

  45. 45

    Balter M. Tracking the human fallout from `mad cow disease.' Science 2000;289:1452-1454
    CrossRef | Web of Science | Medline

  46. 46

    Ghani AC, Ferguson NM, Donnelly CA, Anderson RM. Predicted vCJD mortality in Great Britain. Nature 2000;406:583-584
    CrossRef | Web of Science | Medline

  47. 47

    Scott MR, Will R, Ironside J, et al. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci U S A 1999;96:15137-15142
    CrossRef | Web of Science | Medline

  48. 48

    Phillips N, Bridgeman J, Ferguson-Smith M. BSE inquiry report. Vol. 2. Science. London: Stationery Office, 2000.

  49. 49

    Duffy P, Wolf J, Collins G, DeVoe AG, Streeten B, Cowen D. Possible person-to-person transmission of Creutzfeldt-Jakob disease. N Engl J Med 1974;290:692-693
    Web of Science | Medline

  50. 50

    Bernoulli C, Siegfried J, Baumgartner G, et al. Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery. Lancet 1977;1:478-479
    CrossRef | Web of Science | Medline

  51. 51

    Gibbs CJ, Asher DM, Kobrine A, Amyx HL, Sulima MP, Gajdusek DC. Transmission of Creutzfeldt-Jakob disease to a chimpanzee by electrodes contaminated during neurosurgery. J Neurol Neurosurg Psychiatry 1994;57:757-758
    CrossRef | Web of Science | Medline

  52. 52

    Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts -- Japan, January 1979-May 1996. MMWR Morb Mortal Wkly Rep 1997;46:1066-1069
    Medline

  53. 53

    Tange RA, Troost D, Limburg M. Progressive fatal dementia (Creutzfeldt-Jakob disease) in a patient who received homograft tissue for tympanic membrane closure. Eur Arch Otorhinolaryngol 1989;247:199-201
    Web of Science

  54. 54

    Fradkin JE, Schonberger LB, Mills JL, et al. Creutzfeldt-Jakob disease in pituitary growth hormone recipients in the United States. JAMA 1991;265:880-884
    CrossRef | Web of Science | Medline

  55. 55

    Report on human growth hormone and Creutzfeldt-Jakob disease. Vol. 14. Washington, D.C.: Public Health Service Interagency Coordinating Committee, 1997:1-11.

  56. 56

    Cochius JI, Burns RJ, Blumbergs PC, Mack K, Alderman CP. Creutzfeldt-Jakob disease in a recipient of human pituitary-derived gonadotrophin. Aust N Z J Med 1990;20:592-593
    CrossRef | Medline

  57. 57

    Shibuya S, Higuchi J, Shin R-W, Tateishi J, Kitamoto T. Codon 219 Lys allele of PRNP is not found in sporadic Creutzfeldt-Jakob disease. Ann Neurol 1998;43:826-828
    CrossRef | Web of Science | Medline

  58. 58

    Kaneko K, Zulianello L, Scott M, et al. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc Natl Acad Sci U S A 1997;94:10069-10074
    CrossRef | Web of Science | Medline

  59. 59

    Zulianello L, Kaneko K, Scott M, et al. Dominant-negative inhibition of prion formation diminished by deletion mutagenesis of the prion protein. J Virol 2000;74:4351-4360
    CrossRef | Web of Science | Medline

  60. 60

    Westaway D, Zuliani V, Cooper CM, et al. Homozygosity for prion protein alleles encoding glutamine-171 renders sheep susceptible to natural scrapie. Genes Dev 1994;8:959-969
    CrossRef | Web of Science | Medline

  61. 61

    Hunter N, Moore L, Hosie BD, Dingwall WS, Greig A. Association between natural scrapie and PrP genotype in a flock of Suffolk sheep in Scotland. Vet Rec 1997;140:59-63
    CrossRef | Web of Science | Medline

  62. 62

    St George-Hyslop PH. Molecular genetics of Alzheimer disease. In: Terry RD, Katzman R, Bick KL, Sisodia SS, eds. Alzheimer disease. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 1999:311-26.

  63. 63

    Wilson CA, Doms RW, Lee VM-Y. Intracellular APP processing and Aβ production in Alzheimer disease. J Neuropathol Exp Neurol 1999;58:787-794
    CrossRef | Web of Science | Medline

  64. 64

    Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999;399:Suppl:A23-A31
    CrossRef | Web of Science | Medline

  65. 65

    De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci 2000;113:1857-1870
    Web of Science | Medline

  66. 66

    Yu G, Nishimura M, Arawaka S, et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and βAPP processing. Nature 2000;407:48-54
    CrossRef | Web of Science | Medline

  67. 67

    Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472
    Web of Science | Medline

  68. 68

    Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA 1997;278:1349-1356
    CrossRef | Web of Science | Medline

  69. 69

    Clark LN, Poorkaj P, Wszolek Z, et al. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci U S A 1998;95:13103-13107
    CrossRef | Web of Science | Medline

  70. 70

    Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702-705
    CrossRef | Web of Science | Medline

  71. 71

    Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A 1998;95:7737-7741
    CrossRef | Web of Science | Medline

  72. 72

    Hong M, Zhukareva V, Vogelsberg-Ragaglia V, et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 1998;282:1914-1917
    CrossRef | Web of Science | Medline

  73. 73

    Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000;33:95-130
    CrossRef | Web of Science | Medline

  74. 74

    Brun A. Frontal lobe degeneration of non-Alzheimer type revisited. Dementia 1993;4:126-131
    Medline

  75. 75

    Kertesz A, Munoz DG. Pick's disease and Pick complex. New York: Wiley–Liss, 1998:301.

  76. 76

    Conrad C, Andreadis A, Trojanowski JQ, et al. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol 1997;41:277-281
    CrossRef | Web of Science | Medline

  77. 77

    Goedert M, Spillantini MG, Crowther RA, et al. Tau gene mutation in familial progressive subcortical gliosis. Nat Med 1999;5:454-457
    CrossRef | Web of Science | Medline

  78. 78

    Nussbaum RL, Polymeropoulos MH. Genetics of Parkinson's disease. Hum Mol Genet 1997;6:1687-1691
    CrossRef | Web of Science | Medline

  79. 79

    Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA 1999;281:341-346
    CrossRef | Web of Science | Medline

  80. 80

    Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047
    CrossRef | Web of Science | Medline

  81. 81

    Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature 1997;388:839-840
    CrossRef | Web of Science | Medline

  82. 82

    Shimura H, Hattori N, Kubo S-I, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000;25:302-305
    CrossRef | Web of Science | Medline

  83. 83

    Giasson BI, Duda JE, Murray IVJ, et al. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 2000;290:985-989
    CrossRef | Web of Science | Medline

  84. 84

    Hughes TA, Ross HF, Musa S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000;54:1596-1602
    Web of Science | Medline

  85. 85

    Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990;40:1-8
    Web of Science | Medline

  86. 86

    Hashimoto M, Masliah E. α-Synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol 1999;9:707-720
    CrossRef | Web of Science | Medline

  87. 87

    Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 1998;95:6469-6473
    CrossRef | Web of Science | Medline

  88. 88

    Hudson AJ. Amyotrophic lateral sclerosis and its association with dementia, parkinsonism and other neurological disorders: a review. Brain 1981;104:217-247
    CrossRef | Web of Science | Medline

  89. 89

    Swash M. Clinical features and diagnosis of amyotrophic lateral sclerosis. In: Brown RH Jr, Meininger V, Swash M, eds. Amyotrophic lateral sclerosis. London: Martin Dunitz, 2000:3-30.

  90. 90

    Bobowick AR, Brody JA. Epidemiology of motor-neuron diseases. N Engl J Med 1973;288:1047-1055
    Full Text | Web of Science | Medline

  91. 91

    Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62[Erratum, Nature 1993;364:362.]
    CrossRef | Web of Science | Medline

  92. 92

    Cleveland DW, Liu J. Oxidation versus aggregation -- how do SOD1 mutants cause ALS? Nat Med 2000;6:1320-1321
    CrossRef | Web of Science | Medline

  93. 93

    Martin JB. Molecular basis of the neurodegenerative disorders. N Engl J Med 1999;340:1970-1980[Erratum, N Engl J Med 1999;341:1407.]
    Full Text | Web of Science | Medline

  94. 94

    Lin X, Cummings CJ, Zoghbi HY. Expanding our understanding of polyglutamine diseases through mouse models. Neuron 1999;24:499-502
    CrossRef | Web of Science | Medline

  95. 95

    Paulson HL. Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis)fold. Am J Hum Genet 1999;64:339-345
    CrossRef | Web of Science | Medline

  96. 96

    The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983
    CrossRef | Web of Science | Medline

  97. 97

    Zoghbi HY, Orr HT. Glutamine repeats and neurodegeneration. Annu Rev Neurosci 2000;23:217-247
    CrossRef | Web of Science | Medline

  98. 98

    Gertz HJ, Henkes H, Cervos-Navarro J. Creutzfeldt-Jakob disease: correlation of MRI and neuropathologic findings. Neurology 1988;38:1481-1482
    Web of Science | Medline

  99. 99

    Kitagaki H, Mori E, Yamaji S, et al. Frontotemporal dementia and Alzheimer disease: evaluation of cortical atrophy with automated hemispheric surface display generated with MR images. Radiology 1998;208:431-439
    Web of Science | Medline

  100. 100

    Zerr I, Bodemer M, Gefeller O, et al. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol 1998;43:32-40
    CrossRef | Web of Science | Medline

  101. 101

    Johnson RT, Gibbs CJ Jr. Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N Engl J Med 1998;339:1994-2004
    Full Text | Web of Science | Medline

  102. 102

    Ghiso J, Calero M, Matsubara E, et al. Alzheimer's soluble amyloid β is a normal component of human urine. FEBS Lett 1997;408:105-108
    CrossRef | Web of Science | Medline

  103. 103

    Pitschke M, Prior R, Haupt M, Riesner D. Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat Med 1998;4:832-834
    CrossRef | Web of Science | Medline

  104. 104

    Kirschbaum WR. Jakob-Creutzfeldt disease. Amsterdam: Elsevier, 1968:251.

  105. 105

    Nevin S, McMenemey WH, Behrman S, Jones DP. Subacute spongiform encephalopathy -- a subacute form of encephalopathy attributable to vascular dysfunction (spongiform cerebral atrophy). Brain 1960;83:519-564
    CrossRef | Web of Science | Medline

  106. 106

    Seipelt M, Zerr I, Nau R, et al. Hashimoto's encephalitis as a differential diagnosis of Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 1999;66:172-176
    CrossRef | Web of Science | Medline

  107. 107

    Orr HT, Zoghbi HY. Reversing neurodegeneration: a promise unfolds. Cell 2000;101:1-4
    CrossRef | Web of Science | Medline

  108. 108

    Perrier V, Wallace AC, Kaneko K, Safar J, Prusiner SB, Cohen FE. Mimicking dominant negative inhibition of prion replication through structure-based drug design. Proc Natl Acad Sci U S A 2000;97:6073-6078
    CrossRef | Web of Science | Medline

  109. 109

    Supattapone S, Nguyen H-OB, Cohen FE, Prusiner SB, Scott MR. Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci U S A 1999;96:14529-14534
    CrossRef | Web of Science | Medline

  110. 110

    Priola SA, Raines A, Caughey WS. Porphyrin and phthalocyanine antiscrapie compounds. Science 2000;287:1503-1506
    CrossRef | Web of Science | Medline

  111. 111

    Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177
    CrossRef | Web of Science | Medline

  112. 112

    Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977;1:345-349
    CrossRef | Web of Science | Medline

  113. 113

    van den Pol AN. Narcolepsy: a neurodegenerative disease of the hypocretin system? Neuron 2000;27:415-418
    CrossRef | Web of Science | Medline

  114. 114

    Wilhelmsen KC, Lynch T, Pavlou E, Higgins M, Nygaard TG. Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. Am J Hum Genet 1994;55:1159-1165
    Web of Science | Medline

  115. 115

    Seboun E, Oksenberg JR, Hauser SL. Molecular and genetic aspects of multiple sclerosis. In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, eds. The molecular and genetic basis of neurological disease. 2nd ed. Boston: Butterworth–Heinemann, 1997:631-60.

  116. 116

    Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999;5:170-175
    CrossRef | Web of Science | Medline

  117. 117

    Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717
    CrossRef | Web of Science | Medline

  118. 118

    Benson MD. Amyloidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 7th ed. Vol. 3. New York: McGraw-Hill, 1995:4159-91.

  119. 119

    United Nations. World population prospects: 1998 revision. Vol. 2. The sex and age distribution of the world population. New York: United Nations Department of Economic and Social Affairs Population Division, 1999:1-833.

Citing Articles (242)

Citing Articles

  1. 1

    K. E. Atkins, J. P. Townsend, J. Medlock, A. P. Galvani. (2013) Epidemiological mechanisms of genetic resistance to kuru. Journal of The Royal Society Interface 10:85, 20130331-20130331

  2. 2

    Keita Oishi, Hiroshi Kurahashi, Chan-Gi Pack, Yasushi Sako, Yoshikazu Nakamura. (2013) A bipolar functionality of Q/N-rich proteins: Lsm4 amyloid causes clearance of yeast prions. MicrobiologyOpen 2:3, 415-430

  3. 3

    In Soo Cho, Daryl S. Spinner, Richard J. Kascsak, H. Cliff Meeker, Bo Sook Kim, Seung Yong Park, Georgia Schuller-Levis, Eunkyue Park. (2013) Altered Lymphocyte Proliferation and Innate Immune Function in Scrapie 139A- and ME7-Infected Mice. Viral Immunology 26:3, 192-200

  4. 4

    Zhe Li, Satish Rao, Joel R. Gever, Kartika Widjaja, Stanley B. Prusiner, B. Michael Silber. (2013) Towards Optimization of Arylamides As Novel, Potent, and Brain-Penetrant Antiprion Lead Compounds. ACS Medicinal Chemistry Letters130529120937008

  5. 5

    B. Michael Silber, Satish Rao, Kimberly L. Fife, Alejandra Gallardo-Godoy, Adam R. Renslo, Deepak K. Dalvie, Kurt Giles, Yevgeniy Freyman, Manuel Elepano, Joel R. Gever, Zhe Li, Matthew P. Jacobson, Yong Huang, Leslie Z. Benet, Stanley B. Prusiner. (2013) Pharmacokinetics and Metabolism of 2-Aminothiazoles with Antiprion Activity in Mice. Pharmaceutical Research 30:4, 932-950

  6. 6

    Vladimir N. Uversky. (2013) A decade and a half of protein intrinsic disorder: Biology still waits for physics. Protein Sciencen/a-n/a

  7. 7

    Sina Ghaemmaghami, David W. Colby, Hoang-Oanh B. Nguyen, Shigenari Hayashi, Abby Oehler, Stephen J. DeArmond, Stanley B. Prusiner. (2013) Convergent Replication of Mouse Synthetic Prion Strains. The American Journal of Pathology 182:3, 866-874

  8. 8

    Abdul-Hamid M. Emwas, Zeyad A. Al-Talla, Xianrong Guo, Suliman Al-Ghamdi, Harbi T. Al-Masri. (2013) Utilizing NMR and EPR spectroscopy to probe the role of copper in prion diseases. Magnetic Resonance in Chemistryn/a-n/a

  9. 9

    S. Gharanei, M. Zatyka, D. Astuti, J. Fenton, A. Sik, Z. Nagy, T. G. Barrett. (2013) Vacuolar-type H+-ATPase V1A subunit is a molecular partner of Wolfram syndrome 1 (WFS1) protein, which regulates its expression and stability. Human Molecular Genetics 22:2, 203-217

  10. 10

    Liliana Quintanar, Lina Rivillas-Acevedo, Rafael Grande-Aztatzi, Carlos Z. Gómez-Castro, Trinidad Arcos-López, Alberto Vela. (2013) Copper coordination to the prion protein: Insights from theoretical studies. Coordination Chemistry Reviews 257:2, 429-444

  11. 11

    S. G. Inge-Vechtomov. (2013) The template principle: Paradigm of modern genetics. Russian Journal of Genetics 49:1, 4-9

  12. 12

    C. Warren Olanow, Patrik Brundin. (2013) Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion-Like Disorder?. Movement Disorders 28:1, 31-40

  13. 13

    David Myland Kaufman, Mark J. Milstein. Dementia. In: Kaufman's Clinical Neurology for Psychiatrists. Elsevier, 2013:109-154.

  14. 14

    Brandon B. Holmes, Marc I. Diamond. (2012) Cellular mechanisms of protein aggregate propagation. Current Opinion in Neurology 25:6, 721-726

  15. 15

    Brandon B. Holmes, Marc I. Diamond. (2012) Amyotrophic lateral sclerosis and organ donation: Is there risk of disease transmission?. Annals of Neurology 72:6, 832-836

  16. 16

    Paola Cavaliere, Joan Torrent, Stephanie Prigent, Vincenzo Granata, Kris Pauwels, Annalisa Pastore, Human Rezaei, Adriana Zagari. (2012) Binding of methylene blue to a surface cleft inhibits the oligomerization and fibrillization of prion protein. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

  17. 17

    Xiaojing Cong, Salvatore Bongarzone, Gabriele Giachin, Giulia Rossetti, Paolo Carloni, Giuseppe Legname. (2012) Dominant-negative effects in prion diseases: insights from molecular dynamics simulations on mouse prion protein chimeras. Journal of Biomolecular Structure and Dynamics1-12

  18. 18

    Zong Jie Cui, Zong Qiang Han, Zhi Ying Li. (2012) Modulating protein activity and cellular function by methionine residue oxidation. Amino Acids 43:2, 505-517

  19. 19

    Jingjing Guo, Hui Ren, Lulu Ning, Huanxiang Liu, Xiaojun Yao. (2012) Exploring structural and thermodynamic stabilities of human prion protein pathogenic mutants D202N, E211Q and Q217R. Journal of Structural Biology 178:3, 225-232

  20. 20

    David Teplow, Mingfeng Yang, Robin Roychaudhuri, Eric Pang, Tien-Phat Huynh, Mei-Sha Chen, Shiela Beroukhim. The Amyloid _-Protein and Alzheimer's Disease. CRC Press, 2012:1-85.

  21. 21

    Lary Walker, Rebecca Rosen, Harry LeVine. Pathogenic Protein Strains as Diagnostic and Therapeutic Targets in Alzheimer's Disease. CRC Press, 2012:231-247.

  22. 22

    Vladimir N. Uversky, A. Keith Dunker. Why are we Interested in the Unfolded Peptides and Proteins?. In: Protein and Peptide Folding, Misfolding, and Non-Folding. John Wiley & Sons, Inc., 2012:1-54.

  23. 23

    J. Srinivasa Rao, Brigita Urbanc, Luis Cruz. Computational Studies of Folding and Assembly of Amyloidogenic Proteins. In: Protein and Peptide Folding, Misfolding, and Non-Folding. John Wiley & Sons, Inc., 2012:479-527.

  24. 24

    Rinne , Mikael L. , McGinnis , Scott M. , Samuels , Martin A. , Katz , Joel T. , Loscalzo , Joseph , . (2012) A Startling Decline. New England Journal of Medicine 366:9, 836-842
    Full Text

  25. 25

    Juan Zhou, Efstathios D. Gennatas, Joel H. Kramer, Bruce L. Miller, William W. Seeley. (2012) Predicting Regional Neurodegeneration from the Healthy Brain Functional Connectome. Neuron 73:6, 1216-1227

  26. 26

    Valerie Askanas, W. King Engel, Anna Nogalska. Pathogenesis of Sporadic Inclusion-Body Myositis: Role of Aging and Muscle-Fiber Degeneration, and Accumulation of the Same Proteins as in Alzheimer and Parkinson Brains. In: Muscle Aging, Inclusion-Body Myositis and Myopathies. Wiley-Blackwell, 2012:109-145.

  27. 27

    Husvinee Sundaramurthi, Arulmani Manavalan, Umamaheswari Ramachandran, Jiang-Miao Hu, Siu Kwan Sze, Klaus Heese. (2012) Phenotyping of Tianma-Stimulated Differentiated Rat Neuronal B104 Cells by Quantitative Proteomics. Neurosignals 20:1, 48-60

  28. 28

    Paolo Giannozzi, Karl Jansen, Giovanni La Penna, Velia Minicozzi, Silvia Morante, Giancarlo Rossi, Francesco Stellato. (2012) Zn induced structural aggregation patterns of β-amyloid peptides by first-principle simulations and XAS measurements. Metallomics

  29. 29

    Alessandro Corsaro, Stefano Thellung, Valentina Villa, Mario Nizzari, Antonio Aceto, Tullio Florio. (2012) Recombinant Human Prion Protein Fragment 90–231, a Useful Model to Study Prion Neurotoxicity. OMICS: A Journal of Integrative Biology 16:1-2, 50-59

  30. 30

    Zhenling Peng, Marcin J. Mizianty, Bin Xue, Lukasz Kurgan, Vladimir N. Uversky. (2012) More than just tails: intrinsic disorder in histone proteins. Molecular BioSystems 8:7, 1886

  31. 31

    David A. Smith, David A. Brechtelsbauer. Delirium and Dementia. In: Textbook of Family Medicine. Elsevier, 2012:1078-1090.

  32. 32

    H P Rang, M M Dale, J M Ritter, R J Flower, G Henderson. Neurodegenerative diseases. In: Rang & Dale's Pharmacology. Elsevier, 2012:476-491.

  33. 33

    Liana G. Apostolova, Steven T. DeKosky, Jeffrey L. Cummings. Dementias. In: Neurology in Clinical Practice. Elsevier, 2012:1534-1582.

  34. 34

    Hyun Duk Yang, Dong-Hwan Ho, Myoung-Jea Yi, Wongi Seol, Sang Yun Kim. (2012) Misfolded Proteins in Neurodegenerative Dementias: Molecular Mechanisms. Dementia and Neurocognitive Disorders 11:2, 38

  35. 35

    Raimon Sabaté, Anna Villar-Piqué, Alba Espargaró, Salvador Ventura. (2011) Temperature Dependence of the Aggregation Kinetics of Sup35 and Ure2p Yeast Prions. Biomacromolecules111229154459004

  36. 36

    Tom C. Martinsen, Sylvie L. Benestad, Torfinn Moldal, Helge L. Waldum. (2011) Inhibitors of gastric acid secretion increase the risk of prion infection in mice. Scandinavian Journal of Gastroenterology 46:12, 1418-1422

  37. 37

    E. V. Mikhailova, A. V. Artemov, E. S. Snigirevskaya, T. O. Artamonova, M. A. Khodorkovskii, T. R. Soidla, O. V. Nevzglyadova. (2011) Effect of red pigment on insulin fibril formation in vitro. Cell and Tissue Biology 5:6, 580-585

  38. 38

    Jingjing Guo, Lulu Ning, Hui Ren, Huanxiang Liu, Xiaojun Yao. (2011) Influence of the pathogenic mutations T188K/R/A on the structural stability and misfolding of human prion protein: Insight from molecular dynamics simulations. Biochimica et Biophysica Acta (BBA) - General Subjects

  39. 39

    Yong Wook Jung, In-Hyun Park. (2011) Research Highlights. Regenerative Medicine 6:6, 685-687

  40. 40

    Bin Xue, Marcin J. Mizianty, Lukasz Kurgan, Vladimir N. Uversky. (2011) Protein intrinsic disorder as a flexible armor and a weapon of HIV-1. Cellular and Molecular Life Sciences

  41. 41

    Markus Geissen, Fabienne Leidel, Martin Eiden, Thomas Hirschberger, Christine Fast, Uwe Bertsch, Paul Tavan, Armin Giese, Hans Kretzschmar, Hermann M. Schatzl, Martin H. Groschup. (2011) From High-Throughput Cell Culture Screening to Mouse Model: Identification of New Inhibitor Classes against Prion Disease. ChemMedChem 6:10, 1928-1937

  42. 42

    Sina Ghaemmaghami, Joel C. Watts, Hoang-Oanh Nguyen, Shigenari Hayashi, Stephen J. DeArmond, Stanley B. Prusiner. (2011) Conformational Transformation and Selection of Synthetic Prion Strains. Journal of Molecular Biology 413:3, 527-542

  43. 43

    Mathias Jucker, Lary C. Walker. (2011) Pathogenic protein seeding in alzheimer disease and other neurodegenerative disorders. Annals of Neurology 70:4, 532-540

  44. 44

    Philipp Ottis, Verian Bader, Svenja V. Trossbach, Hans Kretzschmar, Max Michel, S. Rutger Leliveld, Carsten Korth. (2011) Convergence of Two Independent Mental Disease Genes on the Protein Level: Recruitment of Dysbindin to Cell-Invasive Disrupted-In-Schizophrenia 1 Aggresomes. Biological Psychiatry 70:7, 604-610

  45. 45

    S. P. Kapitulets, I. I. Protas, M. K. Nedzved, N. N. Kapitulets, N. N. Poleshchuk. (2011) New Evidence for the Prion Nature of Amyotrophic Leukospongiosis. Neuroscience and Behavioral Physiology 41:8, 857-864

  46. 46

    Yuval Karmon, Arielle Kurzweil, Eric Lindzen, Tomas Holmlund, Bianca Weinstock-Guttman. (2011) Gerstmann–Sträussler–Scheinker syndrome masquerading multiple sclerosis. Journal of the Neurological Sciences 309:1-2, 55-57

  47. 47

    Ana Pinel González, Paloma Montero Escribano, Lorenzo Morlán Gracia, Beatriz Martínez-Menéndez, Yolanda Aladro Benito, Amelia Mendoza Rodríguez, Jesús de Pedro-Cuesta, Miguel Calero. (2011) Enfermedad de Creutzfeldt-Jakob genética fulminante asociada a mutación E200K y polimorfismo M129V. Neurología Argentina

  48. 48

    S. G. Inge-Vechtomov. (2011) Yeast prions as a model of neurodegenerative infectious amyloidoses in humans. Russian Journal of Developmental Biology 42:5, 293-300

  49. 49

    Sanja Kalambura, Neven Voća, Tajana Krička, Zoran Šindrak, Ana Špehar, Dejan Kalambura. (2011) High-Risk Biodegradable Waste Processing By Alkaline Hydrolysis. Archives of Industrial Hygiene and Toxicology 62:3, 249-253

  50. 50

    Mohammed Inayathullah, David B. Teplow. (2011) Structural dynamics of the ΔE22 (Osaka) familial Alzheimer’s disease-linked amyloid β-protein. Amyloid 18:3, 98-107

  51. 51

    B. A. Faucheux, E. Morain, V. Diouron, J.-P. Brandel, D. Salomon, V. Sazdovitch, N. Privat, J.-L. Laplanche, J.-J. Hauw, S. Haïk. (2011) Quantification of surviving cerebellar granule neurones and abnormal prion protein (PrPSc) deposition in sporadic Creutzfeldt-Jakob disease supports a pathogenic role for small PrPSc deposits common to the various molecular subtypes. Neuropathology and Applied Neurobiology 37:5, 500-512

  52. 52

    Seung-Jae Lee, Hee-Sun Lim, Eliezer Masliah, He-Jin Lee. (2011) Protein aggregate spreading in neurodegenerative diseases: Problems and perspectives. Neuroscience Research 70:4, 339-348

  53. 53

    Chongsuk Ryou. Prion Diseases. In: eLS. John Wiley & Sons, Ltd, 2011.

  54. 54

    Hiroshi Kurahashi, Chan-Gi Pack, Shoichiro Shibata, Keita Oishi, Yasushi Sako, Yoshikazu Nakamura. (2011) [PSI+] aggregate enlargement in rnq1 nonprion domain mutants, leading to a loss of prion in yeast. Genes to Cells 16:5, 576-589

  55. 55

    Valentina Villa, Michele Tonelli, Stefano Thellung, Alessandro Corsaro, Bruno Tasso, Federica Novelli, Caterina Canu, Albiana Pino, Katia Chiovitti, Domenico Paludi, Claudio Russo, Anna Sparatore, Antonio Aceto, Vito Boido, Fabio Sparatore, Tullio Florio. (2011) Efficacy of Novel Acridine Derivatives in the Inhibition of hPrP90-231 Prion Protein Fragment Toxicity. Neurotoxicity Research 19:4, 556-574

  56. 56

    Zuzana Krejciova, Steve Pells, Enrico Cancellotti, Paz Freile, Matthew Bishop, Kay Samuel, G Robin Barclay, James W Ironside, Jean C Manson, Marc L Turner, Paul De Sousa, Mark W Head. (2011) Human embryonic stem cells rapidly take up and then clear exogenous human and animal prions in vitro. The Journal of Pathology 223:5, 635-645

  57. 57

    Katharina Stoeck, Inga Zerr. (2011) Cellular immune activation markers neopterin and beta 2-microglobulin are not elevated in the cerebrospinal fluid of patients with Creutzfeldt–Jakob disease. Journal of Neuroimmunology 233:1-2, 228-232

  58. 58

    Alessandro Corsaro, Stefano Thellung, Tonino Bucciarelli, Luca Scotti, Katia Chiovitti, Valentina Villa, Cristina D’Arrigo, Antonio Aceto, Tullio Florio. (2011) High hydrophobic amino acid exposure is responsible of the neurotoxic effects induced by E200K or D202N disease-related mutations of the human prion protein. The International Journal of Biochemistry & Cell Biology 43:3, 372-382

  59. 59

    Zeev Meiner, Esther Kahana, Fanny Baitcher, Amos D. Korczyn, Joab Chapman, Oren S. Cohen, Ron Milo, Judith Aharon-Perez, Oded Abramsky, Ruth Gabizon, Hanna Rosenmann. (2011) Tau and 14-3-3 of genetic and sporadic Creutzfeldt–Jakob disease patients in Israel. Journal of Neurology 258:2, 255-262

  60. 60

    Ruediger Hilker, Jonathan M Brotchie, Joab Chapman. (2011) Pros and cons of a prion-like pathogenesis in Parkinson's disease. BMC Neurology 11:1, 74

  61. 61

    Leonid Breydo, Vladimir N. Uversky. (2011) Role of metal ions in aggregation of intrinsically disordered proteins in neurodegenerative diseases. Metallomics 3:11, 1163

  62. 62

    David M. Asher. Transmissible Spongiform Encephalopathies. In: Nelson Textbook of Pediatrics. Elsevier, 2011:1177.

  63. 63

    Juan P. Olano, Peter F. Weller, Richard L. Guerrant, David H. Walker. Principles of Parasitism. In: Tropical Infectious Diseases: Principles, Pathogens and Practice. Elsevier, 2011:1-7.

  64. 64

    Stanley Fahn, Joseph Jankovic, Mark Hallett. Atypical parkinsonism, parkinsonism-plus syndromes, and secondary parkinsonian disorders. In: Principles and Practice of Movement Disorders. Elsevier, 2011:197-240.

  65. 65

    Yu Bai, Yu-rong Li, Gui-hua Wang, Xiang-mei Zhou, De-ming Zhao. (2010) PrP 106-126 Altered PrP mRNA gene expression in mouse microglia BV-2 Cells. Virologica Sinica 25:6, 440-444

  66. 66

    Thomas Wisniewski, Fernando Goñi. (2010) Immunomodulation for prion and prion-related diseases. Expert Review of Vaccines 9:12, 1441-1452

  67. 67

    A. Vitti, G. Piazzolla, V. Condelli, M. Nuzzaci, M.T. Lanorte, D. Boscia, A. De Stradis, S. Antonaci, P. Piazzolla, C. Tortorella. (2010) Cucumber mosaic virus as the expression system for a potential vaccine against Alzheimer's disease. Journal of Virological Methods 169:2, 332-340

  68. 68

    Elodie Angot, Jennifer A Steiner, Christian Hansen, Jia-Yi Li, Patrik Brundin. (2010) Are synucleinopathies prion-like disorders?. The Lancet Neurology 9:11, 1128-1138

  69. 69

    Douglas B. Kell. (2010) Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples. Archives of Toxicology 84:11, 825-889

  70. 70

    Glenn Millhauser. The Octarepeat Domain of the Prion Protein and Its Role in Metal Ion Coordination and Disease. In: Protein Folding and Metal Ions. CRC Press, 2010:209-223.

  71. 71

    Donald E. Fry. (2010) Prions: Reassessment of the Germ Theory of Disease. Journal of the American College of Surgeons 211:4, 546-552

  72. 72

    Maria Laura Bolognesi, Hoang Ngoc Ai Tran, Matteo Staderini, Alessandra Monaco, Alberto López-Cobeñas, Salvatore Bongarzone, Xevi Biarnés, Pilar López-Alvarado, Nieves Cabezas, Maria Caramelli, Paolo Carloni, J. Carlos Menéndez, Giuseppe Legname. (2010) Discovery of a Class of Diketopiperazines as Antiprion Compounds. ChemMedChem 5:8, 1324-1334

  73. 73

    Kurt Giles, David V. Glidden, Smita Patel, Carsten Korth, Darlene Groth, Azucena Lemus, Stephen J. DeArmond, Stanley B. Prusiner. (2010) Human prion strain selection in transgenic mice. Annals of Neurology 68:2, 151-161

  74. 74

    Katrin Schmidthals, Jonas Helma, Kourosh Zolghadr, Ulrich Rothbauer, Heinrich Leonhardt. (2010) Novel antibody derivatives for proteome and high-content analysis. Analytical and Bioanalytical Chemistry 397:8, 3203-3208

  75. 75

    Silvia Lisa, Massimiliano Meli, Gema Cabello, Ruth Gabizon, Giorgio Colombo, María Gasset. (2010) The structural intolerance of the PrP α-fold for polar substitution of the helix-3 methionines. Cellular and Molecular Life Sciences 67:16, 2825-2838

  76. 76

    Vladimir N Uversky. (2010) Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D 2 concept. Expert Review of Proteomics 7:4, 543-564

  77. 77

    Patricio S. Espinosa, Meriem K. Bensalem-Owen, Dominic B. Fee. (2010) Sporadic Creutzfeldt–Jakob disease presenting as nonconvulsive status epilepticus case report and review of the literature. Clinical Neurology and Neurosurgery 112:6, 537-540

  78. 78

    Vladimir N. Uversky, A. Keith Dunker. (2010) Understanding protein non-folding. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1804:6, 1231-1264

  79. 79

    Khalid Abdel-Galil, Christy Williams, Paul Chambers. (2010) Creutzfeldt–Jakob disease affecting the maxillofacial region: a case report. British Journal of Oral and Maxillofacial Surgery 48:3, 232-233

  80. 80

    Radu I. Stefureac, Claudia Avis Madampage, Olga Andrievskaia, Jeremy S. Lee. (2010) Nanopore analysis of the interaction of metal ions with prion proteins and peptidesThis paper is one of a selection of papers published in this special issue entitled “Canadian Society of Biochemistry, Molecular & Cellular Biology 52nd Annual Meeting — Protein Folding: Principles and Diseases” and has undergone the Journal's usual peer review process.. Biochemistry and Cell Biology 88:2, 347-358

  81. 81

    Stoyan I. Danev, Drozdstoy St. Stoyanov. (2010) Early Noninvasive Diagnosis of Neurodegenerative Diseases. Folia Medica 52:2, 5-13

  82. 82

    Vladimir Kepe, Bernardino Ghetti, Martin R. Farlow, Mara Bresjanac, Karen Miller, Sung-Cheng Huang, Koon-Pong Wong, Jill R. Murrell, Pedro Piccardo, Francine Epperson, Grega Repovš, Lojze M. Smid, Andrej Petrič, Prabha Siddarth, Jie Liu, Nagichettiar Satyamurthy, Gary W. Small, Jorge R. Barrio. (2010) PET of Brain Prion Protein Amyloid in Gerstmann-Sträussler-Scheinker Disease. Brain Pathology 20:2, 419-430

  83. 83

    Sriram Venneti. (2010) Prion Diseases. Clinics in Laboratory Medicine 30:1, 293-309

  84. 84

    Min Jeong Park, Hee Young Jo, Sang-Myung Cheon, Sun Seob Choi, Yong-Sun Kim, Jae Woo Kim. (2010) A Case of Gerstmann-Sträussler-Scheinker Disease. Journal of Clinical Neurology 6:1, 46

  85. 85

    Claudia Avis Madampage, Olga Andrievskaia, Jeremy S. Lee. (2010) Nanopore detection of antibody prion interactions. Analytical Biochemistry 396:1, 36-41

  86. 86

    Joshua A. Sonnen, C. Dirk Keene, Robert F. Hevner, Thomas J. Montine. Molecular Pathology. In: Essential Concepts in Molecular Pathology. Elsevier, 2010:373-398.

  87. 87

    Hiroshi Shimizu, Mitsunori Yamada, Nae Matsubara, Hiroki Takano, Yoshitaka Umeda, Yasuhiro Kawase, Tetsuyuki Kitamoto, Masatoyo Nishizawa, Hitoshi Takahashi. (2009) Creutzfeldt-Jakob disease with an M232R substitution: report of a patient showing slowly progressive disease with abundant plaque-like PrP deposits in the cerebellum. Neuropathology 29:6, 735-743

  88. 88

    Reema Roshan, Tanay Ghosh, Vinod Scaria, Beena Pillai. (2009) MicroRNAs: novel therapeutic targets in neurodegenerative diseases. Drug Discovery Today 14:23-24, 1123-1129

  89. 89

    Maurizio Polano, Alpan Bek, Federico Benetti, Marco Lazzarino, Giuseppe Legname. (2009) Structural Insights into Alternate Aggregated Prion Protein Forms. Journal of Molecular Biology 393:5, 1033-1042

  90. 90

    Michelangelo Mancuso, Gabriele Siciliano, Sabina Capellari, Daniele Orsucci, Policarpo Moretti, Giuseppe Di Fede, Silvia Suardi, Rosaria Strammiello, Piero Parchi, Fabrizio Tagliavini, Luigi Murri. (2009) Creutzfeldt–Jakob disease with E200K PRNP mutation: a case report and revision of the literature. Neurological Sciences 30:5, 417-420

  91. 91

    Kathleen A. Maguire-Zeiss, Howard J. Federoff. (2009) Immune-Directed Gene Therapeutic Development for Alzheimer’s, Prion, and Parkinson’s Diseases. Journal of Neuroimmune Pharmacology 4:3, 298-308

  92. 92

    Laura Colombo, Paola Piovesan, Orlando Ghirardi, Mario Salmona, Gianluigi Forloni. (2009) ST1859 reduces prion infectivity and increase survival in experimental scrapie. Archives of Virology 154:9, 1539-1544

  93. 93

    L. López Carreira, V. Armesto Pérez, P. González Gutiérrez, A. Cela Aira, A. Gayol Méndez, S. Baleato González. (2009) Enfermedad de Creutzfeldt-Jakob: hallazgos en resonancia magnética. Radiología 51:5, 487-494

  94. 94

    R. Sabaté, V. Castillo, A. Espargaró, Sven J. Saupe, S. Ventura. (2009) Energy barriers for HET-s prion forming domain amyloid formation. FEBS Journal 276:18, 5053-5064

  95. 95

    Baptiste A. Faucheux, Nicolas Privat, Jean-Philippe Brandel, Véronique Sazdovitch, Jean-Louis Laplanche, Claude-Alain Maurage, Jean-Jacques Hauw, Stéphane Haïk. (2009) Loss of Cerebellar Granule Neurons Is Associated With Punctate but Not With Large Focal Deposits of Prion Protein in Creutzfeldt-Jakob Disease. Journal of Neuropathology & Experimental Neurology 68:8, 892-901

  96. 96

    Sarah Medina, Avril Hatherall, Debra Parchaliuk, Catherine Robertson, Stephanie A. Booth. (2009) Quantitative Reverse-Transcription Polymerase Chain Reaction Analysis of Alzheimer's-Associated Genes in Mouse Scrapie. Journal of Toxicology and Environmental Health, Part A 72:17-18, 1075-1082

  97. 97

    Tamas Revesz, Janice L. Holton, Tammaryn Lashley, Gordon Plant, Blas Frangione, Agueda Rostagno, Jorge Ghiso. (2009) Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathologica 118:1, 115-130

  98. 98

    Howard J. Federoff. (2009) Development of vaccination approaches for the treatment of neurological diseases. The Journal of Comparative Neurology 515:1, 4-14

  99. 99

    Georgia Duckworth, Adam Fraise, Gary French, Savita Gossain, Peter Hawkey, Donald Jeffries, E Smith, Mark Wilcox. Special problems of infections. In: Ayliffe's Control of Healthcare-Associated Infection Fifth Edition. CRC Press, 2009:237-302.

  100. 100

    Hiroshi Kurahashi, Shoichiro Shibata, Masao Ishiwata, Yoshikazu Nakamura. (2009) Selfish prion of Rnq1 mutant in yeast. Genes to Cells 14:5, 659-668

  101. 101

    Michael D Geschwind. (2009) Clinical trials for prion disease: difficult challenges, but hope for the future. The Lancet Neurology 8:4, 304-306

  102. 102

    Roger E. Kelley, Alireza Minagar. (2009) Memory Complaints and Dementia. Medical Clinics of North America 93:2, 389-406

  103. 103

    Alessandro Corsaro, Stefano Thellung, Katia Chiovitti, Valentina Villa, Alessandro Simi, Federica Raggi, Domenico Paludi, Claudio Russo, Antonio Aceto, Tullio Florio. (2009) Dual Modulation of ERK1/2 and p38 MAP Kinase Activities Induced by Minocycline Reverses the Neurotoxic Effects of the Prion Protein Fragment 90–231. Neurotoxicity Research 15:2, 138-154

  104. 104

    Andreas Müller-Schiffmann, Benjamin Petsch, S. Rutger Leliveld, Janine Muyrers, Agnieska Salwierz, Christian Mangels, Stephan Schwarzinger, Detlev Riesner, Lothar Stitz, Carsten Korth. (2009) Complementarity determining regions of an anti-prion protein scFv fragment orchestrate conformation specificity and antiprion activity. Molecular Immunology 46:4, 532-540

  105. 105

    (2009) Polymer solutions and melts. Polymer Science Series A 51:1, 14-25

  106. 106

    Nathalie M. Veith, Helmut Plattner, Claudia A.O. Stuermer, Walter J. Schulz-Schaeffer, Alexander Bürkle. (2009) Immunolocalisation of PrPSc in scrapie-infected N2a mouse neuroblastoma cells by light and electron microscopy. European Journal of Cell Biology 88:1, 45-63

  107. 107

    THOMAS A. TOUSSEYN, JEFFREY P. SIMKO, DAVID A. GASKIN, STEPHEN J. DeARMOND. The Molecular and Genetic Basis of Neurodegenerative Diseases. In: Modern Surgical Pathology. Elsevier, 2009:2039-2068.

  108. 108

    Richard Prayson. Molecular Neuropathology. In: Cell and Tissue Based Molecular Pathology. Elsevier, 2009:195-213.

  109. 109

    Joshua A. Sonnen, C. Dirk Keene, Robert F. Hevner, Thomas J. Montine. Molecular Pathology. In: Molecular Pathology. Elsevier, 2009:551-587.

  110. 110

    Giuseppe Scalabrino, Daniela Veber, Elena Mutti. (2008) Experimental and clinical evidence of the role of cytokines and growth factors in the pathogenesis of acquired cobalamin-deficient leukoneuropathy. Brain Research Reviews 59:1, 42-54

  111. 111

    Valeriy G. Ostapchenko, Natallia Makarava, Regina Savtchenko, Ilia V. Baskakov. (2008) The Polybasic N-Terminal Region of the Prion Protein Controls the Physical Properties of Both the Cellular and Fibrillar Forms of PrP. Journal of Molecular Biology 383:5, 1210-1224

  112. 112

    Katharina Stoeck, Klaus Hess, Lorenz Amsler, Tobias Eckert, Dieter Zimmermann, Adriano Aguzzi, Markus Glatzel. (2008) Heightened incidence of sporadic Creutzfeldt-Jakob disease is associated with a shift in clinicopathological profiles. Journal of Neurology 255:10, 1464-1472

  113. 113

    Alicja Lerner, Anto Bagic. (2008) Olfactory pathogenesis of idiopathic Parkinson disease revisited. Movement Disorders 23:8, 1076-1084

  114. 114

    Taro Shimono, Takahiro Tsuboyama, Masatomo Kuwabara, Sung-woon Im, Yukinobu Yagyu, Izumi Imaoka, Ryuichiro Ashikaga, Makoto Hosono, Takamichi Murakami. (2008) Discordance of motion artifacts on magnetic resonance imaging in Creutzfeldt-Jakob disease: comparison of diffusion-weighted and conventional imaging sequences. Radiation Medicine 26:3, 151-155

  115. 115

    Vladimir N. Uversky, Anthony L. Fink. Amyloid Fibril Formation of Natively Unfolded Proteins. In: Protein Science Encyclopedia. Wiley-VCH Verlag GmbH & Co. KGaA, 2008.

  116. 116

    Ilia V. Baskakov. Thermodynamics of Amyloid Formation. In: Protein Science Encyclopedia. Wiley-VCH Verlag GmbH & Co. KGaA, 2008.

  117. 117

    A. A. Rubel, A. F. Saifitdinova, A. G. Lada, A. A. Nizhnikov, S. G. Inge-Vechtomov, A. P. Galkin. (2008) Yeast chaperone Hsp104 controls gene expression at the posttranscriptional level. Molecular Biology 42:1, 110-116

  118. 118

    Ryan Wada, Walter Kucharczyk. (2008) Prion Infections of the Brain. Neuroimaging Clinics of North America 18:1, 183-191

  119. 119

    Daniel G. du Plessis. (2008) Prion Protein Disease and Neuropathology of Prion Disease. Neuroimaging Clinics of North America 18:1, 163-182

  120. 120

    Michel O. Steinmetz, Zrinka Gattin, Rene Verel, Barbara Ciani, Thusnelda Stromer, Janelle M. Green, Peter Tittmann, Clemens Schulze-Briese, Heinz Gross, Wilfred F. van Gunsteren, Beat H. Meier, Louise C. Serpell, Shirley A. Müller, Richard A. Kammerer. (2008) Atomic Models of De Novo Designed ccβ-Met Amyloid-Like Fibrils. Journal of Molecular Biology 376:3, 898-912

  121. 121

    Steven T. DeKosky, Daniel I. Kaufer, Ronald L. Hamilton, David A. Wolk, Oscar L. Lopez. The Dementias. In: Neurology in Clinical Practice. Elsevier, 2008:1855-1907.

  122. 122

    BibliographyUSEFUL WEBSITES. In: Mims' Medical Microbiology. Elsevier, 2008:625-633.

  123. 123

    David Myland Kaufman. Demencia. In: Neurología clínica para psiquiatras. Elsevier, 2008:111-142.

  124. 124

    Domenico Paludi, Stefano Thellung, Katia Chiovitti, Alessandro Corsaro, Valentina Villa, Claudio Russo, Adriana Ianieri, Uwe Bertsch, Hans A. Kretzschmar, Antonio Aceto, Tullio Florio. (2007) Different structural stability and toxicity of PrP ARR and PrP ARQ sheep prion protein variants. Journal of Neurochemistry 103:6, 2291-2300

  125. 125

    S. Ghaemmaghami, P.-W. Phuan, B. Perkins, J. Ullman, B. C. H. May, F. E. Cohen, S. B. Prusiner. (2007) From the Cover: Cell division modulates prion accumulation in cultured cells. Proceedings of the National Academy of Sciences 104:46, 17971-17976

  126. 126

    Rebecca Buckner, David Asher. Prions in the Food Chain. In: Microbial Food Contamination, Second Edition. CRC Press, 2007.

  127. 127

    J. Richard Hesp, Neil D.H. Raven, J. Mark Sutton. (2007) A role for His155 in binding of human prion peptide144–167 to immobilised prion protein. Biochemical and Biophysical Research Communications 362:3, 695-699

  128. 128

    S. Rutger Leliveld, Carsten Korth. (2007) The use of conformation-specific ligands and assays to dissect the molecular mechanisms of neurodegenerative diseases. Journal of Neuroscience Research 85:11, 2285-2297

  129. 129

    Thomas Wisniewski, Einar M. Sigurdsson. (2007) Therapeutic approaches for prion and Alzheimer's diseases. FEBS Journal 274:15, 3784-3798

  130. 130

    Francisco Molina-Holgado, Robert C. Hider, Alessandra Gaeta, Robert Williams, Paul Francis. (2007) Metals ions and neurodegeneration. BioMetals 20:3-4, 639-654

  131. 131

    Ilaria Filesi, Alessio Cardinale, Sonia Mattei, Silvia Biocca. (2007) Selective re-routing of prion protein to proteasomes and alteration of its vesicular secretion prevent PrP Sc formation. Journal of Neurochemistry 101:6, 1516-1526

  132. 132

    Glenn L. Millhauser. (2007) Copper and the Prion Protein: Methods, Structures, Function, and Disease. Annual Review of Physical Chemistry 58:1, 299-320

  133. 133

    S. Yin, N. Pham, S. Yu, C. Li, P. Wong, B. Chang, S.-C. Kang, E. Biasini, P. Tien, D. A. Harris, M.-S. Sy. (2007) Human prion proteins with pathogenic mutations share common conformational changes resulting in enhanced binding to glycosaminoglycans. Proceedings of the National Academy of Sciences 104:18, 7546-7551

  134. 134

    Yong Zhang, Xin Zhao, Peng-Ye Wang. (2007) Molecular dynamics study of the fibril elongation of the prion protein fragment PrP106–126. Journal of Theoretical Biology 245:2, 238-242

  135. 135

    Gábor G. Kovács, Ellen Gelpi, Attila Lehotzky, Romana Höftberger, Anna Erdei, Herbert Budka, Judit Ovádi. (2007) The brain-specific protein TPPP/p25 in pathological protein deposits of neurodegenerative diseases. Acta Neuropathologica 113:2, 153-161

  136. 136

    Roberto Scatena, Giuseppe E Martorana, Patrizia Bottoni, Giorgia Botta, Paola Pastore, Bruno Giardina. (2007) An update on pharmacological approaches to neurodegenerative diseases. Expert Opinion on Investigational Drugs 16:1, 59-72

  137. 137

    Dementia. In: Clinical Neurology for Psychiatrists. Elsevier, 2007:111-156.

  138. 138

    HP Rang, MM Dale, JM Ritter, RJ Flower. Neurodegenerative diseases. In: Rang & Dale's Pharmacology. Elsevier, 2007:508-522.

  139. 139

    Paul Brown. Transmissible Spongiform Encephalopathy. In: Textbook of Clinical Neurology. Elsevier, 2007:969-979.

  140. 140

    Degeneration in the Nervous System. In: Jubb, Kennedy & Palmer's Pathology of Domestic Animals. Elsevier, 2007:345-393.

  141. 141

    Dementia. In: Clinical Neurology for Psychiatrists. Elsevier, 2007:111-156.

  142. 142

    Gilberto Corbellini, Chiara Preti. (2006) Epistemological and moral lessons from the history of neurodegenerative diseases. Rendiconti Lincei 17:4, 377-392

  143. 143

    A. P. Galkin, L. N. Mironova, G. A. Zhuravleva, S. G. Inge-Vechtomov. (2006) Yeast prions, mammalian amyloidoses, and the problem of proteomic networks. Russian Journal of Genetics 42:11, 1313-1323

  144. 144

    John W. Phillis, Lloyd A. Horrocks, Akhlaq A. Farooqui. (2006) Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: Their role and involvement in neurological disorders. Brain Research Reviews 52:2, 201-243

  145. 145

    Richard A. Kammerer, Michel O. Steinmetz. (2006) De novo design of a two-stranded coiled-coil switch peptide. Journal of Structural Biology 155:2, 146-153

  146. 146

    Viktória Jószai, Zoltán Nagy, Katalin Ősz, Daniele Sanna, Giuseppe Di Natale, Diego La Mendola, Giuseppe Pappalardo, Enrico Rizzarelli, Imre Sóvágó. (2006) Transition metal complexes of terminally protected peptides containing histidyl residues. Journal of Inorganic Biochemistry 100:8, 1399-1409

  147. 147

    Lary C. Walker, Harry LeVine, Mark P. Mattson, Mathias Jucker. (2006) Inducible proteopathies. Trends in Neurosciences 29:8, 438-443

  148. 148

    Lary Walker, Harry LeVine, Mathias Jucker. (2006) Koch’s postulates and infectious proteins. Acta Neuropathologica 112:1, 1-4

  149. 149

    Natallia Makarava, Olga V. Bocharova, Vadim V. Salnikov, Leonid Breydo, Maighdlin Anderson, Ilia V. Baskakov. (2006) Dichotomous versus palm-type mechanisms of lateral assembly of amyloid fibrils. Protein Science 15:6, 1334-1341

  150. 150

    Sara Vasan, Phyllus Y. Mong, Abraham Grossman. (2006) Interaction of Prion Protein with Small Highly Structured RNAs: Detection and Characterization of PrP-Oligomers. Neurochemical Research 31:5, 629-637

  151. 151

    Tapan K. Chaudhuri, Subhankar Paul. (2006) Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS Journal 273:7, 1331-1349

  152. 152

    Maighdlin Anderson, Olga V. Bocharova, Natallia Makarava, Leonid Breydo, Vadim V. Salnikov, Ilia V. Baskakov. (2006) Polymorphism and Ultrastructural Organization of Prion Protein Amyloid Fibrils: An Insight from High Resolution Atomic Force Microscopy. Journal of Molecular Biology 358:2, 580-596

  153. 153

    Y ZHANG, L DAI, M IWAMOTO, Z OUYANG. (2006) Molecular dynamics study on the conformational transition of prion induced by the point mutation: F198S. Thin Solid Films 499:1-2, 224-228

  154. 154

    Rachel L. Stricof, Patricia P. Lillquist, Nadia Thomas, Ermias D. Belay, Lawrence B. Schonberger, Dale L. Morse. (2006) An Investigation of Potential Neurosurgical Transmission of Creutzfeldt‐Jakob Disease: Challenges and Lessons Learned • . Infection Control and Hospital Epidemiology 27:3, 302-304

  155. 155

    Angelica A. Saetta, Nikolaos V. Michalopoulos, George Malamis, Polyanthi I. Papanastasiou, Niki Mazmanian, Maria Karlou, Anastasios Kouzoupis, Penelope Korkolopoulou, Efstratios Patsouris. (2006) Analysis of PRNP Gene Codon 129 Polymorphism in the Greek Population. European Journal of Epidemiology 21:3, 211-215

  156. 156

    A BERGSTROM, T JENSEN, P HEEGAARD, H CORDES, V HANSEN, H LAURSEN, P LIND. (2006) Short-term Study of the Uptake of PrPSc by the Peyer's Patches in Hamsters after Oral Exposure to Scrapie. Journal of Comparative Pathology 134:2-3, 126-133

  157. 157

    Robert D Moir, Rudolph E Tanzi. Protein Aggregation and Human Disorders. In: Encyclopedia of Life Sciences. John Wiley & Sons, Ltd, 2006.

  158. 158

    J. Avila, I. Santa-María, M. Pérez, F. Hernández, F. Moreno. (2006) Tau Phosphorylation, Aggregation, and Cell Toxicity. Journal of Biomedicine and Biotechnology 2006, 1-5

  159. 159

    Alessandra Gaeta, Robert C Hider. (2005) The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. British Journal of Pharmacology 146:8, 1041-1059

  160. 160

    Gianluigi Zanusso, Salvatore Monaco. (2005) Molecular mechanisms of human prion diseases. Drug Discovery Today: Disease Mechanisms 2:4, 511-518

  161. 161

    P NICO, B LOBAOSOARES, M LANDEMBERGER, W MARQUESJR, C TASCA, C DEMELLO, R WALZ, C CARLOTTIJR, R BRENTANI, A SAKAMOTO. (2005) Impaired exercise capacity, but unaltered mitochondrial respiration in skeletal or cardiac muscle of mice lacking cellular prion protein. Neuroscience Letters 388:1, 21-26

  162. 162

    Gábor G. Kovács, Maria Puopolo, Anna Ladogana, Maurizio Pocchiari, Herbert Budka, Cornelia van Duijn, Steven J. Collins, Alison Boyd, Antonio Giulivi, Mike Coulthart, Nicole Delasnerie-Laupretre, Jean Philippe Brandel, Inga Zerr, Hans A. Kretzschmar, Jesus de Pedro-Cuesta, Miguel Calero-Lara, Markus Glatzel, Adriano Aguzzi, Matthew Bishop, Richard Knight, Girma Belay, Robert Will, Eva Mitrova. (2005) Genetic prion disease: the EUROCJD experience. Human Genetics 118:2, 166-174

  163. 163

    J ENA. (2005) Prions: Who Should Worry about Them?. Archives of Medical Research 36:6, 622-627

  164. 164

    Georg Pauli. (2005) Tissue Safety in View of CJD and Variant CJD. Cell and Tissue Banking 6:3, 191-200

  165. 165

    Patrícia Barreto Costa Nico, Fernanda de-Paris, Elsa Regina Vinadé, Olavo B. Amaral, Isabel Rockenbach, Bruno Lobão Soares, Ricardo Guarnieri, Lauro Wichert-Ana, Fabrício Calvo, Roger Walz, Ivan Izquierdo, Américo C. Sakamoto, Ricardo Brentani, Vilma R. Martins, Marino Muxfeldt Bianchin. (2005) Altered behavioural response to acute stress in mice lacking cellular prion protein. Behavioural Brain Research 162:2, 173-181

  166. 166

    Olga V. Bocharova, Leonid Breydo, Vadim V. Salnikov, Andrew C. Gill, Ilia V. Baskakov. (2005) Synthetic prions generated in vitro are similar to a newly identified subpopulation of PrP Sc from sporadic Creutzfeldt-Jakob Disease. Protein Science 14:5, 1222-1232

  167. 167

    Michel O. Steinmetz, Carlos Garca-Echeverra, Richard A. Kammerer. (2005) Design of a Coiled-Coil-based Model Peptide System to Explore the Fundamentals of Amyloid Fibril Formation. International Journal of Peptide Research and Therapeutics 11:1, 43-52

  168. 168

    Gérard Lucotte, Géraldine Mercier. (2005) The population distribution of the Met allele at the PRNP129 polymorphism (a high risk factor for Creutzfeldt-Jakob disease) in various regions of France and in West Europe. Infection, Genetics and Evolution 5:2, 141-144

  169. 169

    Naomi S. Hachiya, Kota Watanabe, Makiko Y. Kawabata, Akiko Jozuka, Yoshimichi Kozuka, Yuji Sakasegawa, Kiyotoshi Kaneko. (2005) Prion protein with Y145STOP mutation induces mitochondria-mediated apoptosis and PrP-containing deposits in vitro. Biochemical and Biophysical Research Communications 327:3, 894-899

  170. 170

    (2005) Variant Creutzfeldt-Jakob Disease. Transfusion Medicine and Hemotherapy 32:3-4, 227-236

  171. 171

    Giuseppe Di Natale, Giuseppe Impellizzeri, Giuseppe Pappalardo. (2005) Conformational properties of peptide fragments homologous to the 106–114 and 106–126 residues of the human prion protein: a CD and NMR spectroscopic study. Organic & Biomolecular Chemistry 3:3, 490

  172. 172

    Maurizio Remelli, Martina Donatoni, Remo Guerrini, Anna Janicka, Pierluigi Pretegiani, Henryk Kozłowski. (2005) Copper-ion interaction with the 106–113 domain of the prion protein: a solution-equilibria study on model peptides. Dalton Transactions:17, 2876

  173. 173

    Isamu Mori, Yukihiro Nishiyama, Takashi Yokochi, Yoshinobu Kimura. (2005) Olfactory transmission of neurotropic viruses. Journal of Neurovirology 11:2, 129-137

  174. 174

    P. Brown, C. R. Abee. (2005) Working with Transmissible Spongiform Encephalopathy Agents. ILAR Journal 46:1, 44-52

  175. 175

    Bao Ting Zhu. Human and Animal Spongiform Encephalopathies are Autoimmune Diseases: A Novel Theory and its Supporting Evidence. Elsevier, 2005:155-190.

  176. 176

    Simon Megy, Gildas Bertho, Sergey A. Kozin, Pascale Debey, Gaston Hui Bon Hoa, Jean-Pierre Girault. (2004) Possible role of region 152-156 in the structural duality of a peptide fragment from sheep prion protein. Protein Science 13:12, 3151-3160

  177. 177

    Stphane Hak, Katell Peoc'h, Jean-Philippe Brandel, Nicolas Privat, Jean-Louis Laplanche, Baptiste A. Faucheux, Jean-Jacques Hauw. (2004) Striking PrPsc heterogeneity in inherited prion diseases with the D178N mutation. Annals of Neurology 56:6, 910-911

  178. 178

    Pawel P. Liberski, Beata Sikorska, Jolanta Bratosiewicz-Wasik, D. Carleton Gajdusek, Paul Brown. (2004) Neuronal cell death in transmissible spongiform encephalopathies (prion diseases) revisited: from apoptosis to autophagy. The International Journal of Biochemistry & Cell Biology 36:12, 2473-2490

  179. 179

    Neena S Rane, Jesse L Yonkovich, Ramanujan S Hegde. (2004) Protection from cytosolic prion protein toxicity by modulation of protein translocation. The EMBO Journal 23:23, 4550-4559

  180. 180

    Neil R. Cashman, Byron Caughey. (2004) Prion diseases — close to effective therapy?. Nature Reviews Drug Discovery 3:10, 874-884

  181. 181

    Alfredo Ulloa-Aguirre, Jo Ann Janovick, Shaun P. Brothers, P. Michael Conn. (2004) Pharmacologic Rescue of Conformationally-Defective Proteins: Implications for the Treatment of Human Disease. Traffic 5:11, 821-837

  182. 182

    Christopher A Ross, Michelle A Poirier. (2004) Protein aggregation and neurodegenerative disease. Nature Medicine 10:7, S10-S17

  183. 183

    E. I. Agorogiannis, G. I. Agorogiannis, A. Papadimitriou, G. M. Hadjigeorgiou. (2004) Protein misfolding in neurodegenerative diseases. Neuropathology and Applied Neurobiology 30:3, 215-224

  184. 184

    Marcin Sadowski, Thomas Wisniewski. (2004) Vaccines for conformational disorders. Expert Review of Vaccines 3:3, 279-290

  185. 185

    Christoph Hundt, Stefan Weiss. (2004) The prion-like protein Doppel fails to interact with itself, the prion protein and the 37 kDa/67 kDa laminin receptor in the yeast two-hybrid system. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1689:1, 1-5

  186. 186

    Tatsumi Korenaga, Xiaoying Fu, Yanming Xing, Takatoshi Matsusita, Kazunao Kuramoto, Seigo Syumiya, Kazuhiro Hasegawa, Hironobu Naiki, Masaki Ueno, Tokuhiro Ishihara, Masanori Hosokawa, Masayuki Mori, Keiichi Higuchi. (2004) Tissue Distribution, Biochemical Properties, and Transmission of Mouse Type A AApoAII Amyloid Fibrils. The American Journal of Pathology 164:5, 1597-1606

  187. 187

    Barbara Belosi, Elena Gaggelli, Remo Guerrini, Henryk Kozłowski, Marek Łuczkowski, Francesca M. Mancini, Maurizio Remelli, Daniela Valensin, Gianni Valensin. (2004) Copper Binding to the Neurotoxic Peptide PrP106-126: Thermodynamic and Structural Studies. ChemBioChem 5:3, 349-359

  188. 188

    Christopher E. Beisel, David M. Morens. (2004) Variant Creutzfeldt‐Jakob Disease and the Acquired and Transmissible Spongiform Encephalopathies. Clinical Infectious Diseases 38:5, 697-704

  189. 189

    Roger Y. Dodd, David A. Leiby. (2004) Emerging Infectious Threats to the Blood Supply. Annual Review of Medicine 55:1, 191-207

  190. 190

    Deborah A Burton, Grainne Nicholson, George M Hall. (2004) Anaesthesia in Elderly Patients with Neurodegenerative Disorders. Drugs & Aging 21:4, 229-242

  191. 191

    Andreas Modler, Heinz Fabian, Fabian Sokolowski, Gudrun Lutsch, Klaus Gast, Gregor Damaschun. (2004) Polymerization of proteins into amyloid protofibrils shares common critical oligomeric states but differs in the mechanisms of their formation. Amyloid 11:4, 215-231

  192. 192

    Hitaru Kishida, Yuji Sakasegawa, Kota Watanabe, Yoshio Yamakawa, Masahiro Nishijima, Yoshiyuki Kuroiwa, Naomi S Hachiya, Kiyotoshi Kaneko. (2004) Non-glycosylphosphatidylinositol (GPI)-anchored recombinant prion protein with dominant-negative mutation inhibits PrP Sc replication in vitro . Amyloid 11:1, 14-20

  193. 193

    Helen C. Ardley, Philip A. Robinson. (2004) The Role of Ubiquitin-Protein Ligases in Neurodegenerative Disease. Neurodegenerative Diseases 1:2-3, 71-87

  194. 194

    Kevin St.P. McNaught. Proteolytic Dysfunction in Neurodegenerative Disorders. Elsevier, 2004:95-119.

  195. 195

    Yiling Hu, Li Liu, Eric B Kmiec. (2003) Reduction of Htt inclusion formation in strains of Saccharomyces cerevisiae deficient in certain DNA repair functions: a statistical analysis of phenotype. Experimental Cell Research 291:1, 46-55

  196. 196

    Ralph Zahn. (2003) The Octapeptide Repeats in Mammalian Prion Protein Constitute a pH-dependent Folding and Aggregation Site. Journal of Molecular Biology 334:3, 477-488

  197. 197

    Tamas Revesz, Janice L. Holton. (2003) Anatamopathological spectrum of tauopathies. Movement Disorders 18:S6, 13-20

  198. 198

    Thomas Weber. Prion Diseases. In: Clinical Neurovirology. Informa Healthcare, 2003.

  199. 199

    Merlini , Giampaolo , Bellotti , Vittorio , . (2003) Molecular Mechanisms of Amyloidosis. New England Journal of Medicine 349:6, 583-596
    Full Text

  200. 200

    Jeffrey L. Cummings. (2003) Toward a molecular neuropsychiatry of neurodegenerative diseases. Annals of Neurology 54:2, 147-154

  201. 201

    Lal K. Tanwani, Christian D. Furman, Christine S. Ritchie. (2003) Diagnostic Challenges in Creutzfeldt-Jakob Disease: Case Report. Southern Medical Journal 96:8, 832-835

  202. 202

    Barkur S Shastry. (2003) Neurodegenerative disorders of protein aggregation. Neurochemistry International 43:1, 1-7

  203. 203

    Ramanujan S. Hegde, Neena S. Rane. (2003) Prion protein trafficking and the development of neurodegeneration. Trends in Neurosciences 26:7, 337-339

  204. 204

    M Plamont. (2003) Variation at the ADAM10 gene locus is not associated with Creutzfeldt–Jakob disease. Neuroscience Letters 344:2, 132-134

  205. 205

    Philip Bardin, Gwendolyn Sanderson. Human Experimental Models of Virus Infection and Asthma. In: Respiratory Infections in Allergy and Asthma. CRC Press, 2003.

  206. 206

    I Ramasamy, M Law, S Collins, F Brook. (2003) Organ distribution of prion proteins in variant Creutzfeldt-Jakob disease. The Lancet Infectious Diseases 3:4, 214-222

  207. 207

    Oscar E. Mendez, Jingzi Shang, Charles A. Jungreis, Daniel I. Kaufer. (2003) Diffusion-Weighted MRI in Creutzfeldt-Jakob Disease: A Better Diagnostic Marker Than CSF Protein 14-3-3?. Journal of Neuroimaging 13:2, 147-151

  208. 208

    John Collinge, Sebastian Brandner, Angus Kennedy, Martin Rossor, Peter Smith, John Stevens, Peter Rudge. (2003) A 38-year-old man with a 9 month history of neurological and cognitive impairment. The Lancet Neurology 2:3, 189-194

  209. 209

    Zanusso , Gianluigi , Ferrari , Sergio , Cardone , Franco , Zampieri , Paolo , Gelati , Matteo , Fiorini , Michele , Farinazzo , Alessia , Gardiman , Marina , Cavallaro , Tiziana , Bentivoglio , Marina , Righetti , Pier Giorgio , Pocchiari , Maurizio , Rizzuto , Nicola , Monaco , Salvatore , . (2003) Detection of Pathologic Prion Protein in the Olfactory Epithelium in Sporadic Creutzfeldt–Jakob Disease. New England Journal of Medicine 348:8, 711-719
    Free Full Text

  210. 210

    David N. Irani, Richard T. Johnson. (2003) Diagnosis and Prevention of Bovine Spongiform Encephalopathy and Variant Creutzfeldt-Jakob Disease. Annual Review of Medicine 54:1, 305-319

  211. 211

    E Sigurdsson. (2003) Anti-prion antibodies for prophylaxis following prion exposure in mice. Neuroscience Letters 336:3, 185-187

  212. 212

    Jeffrey Cummings, Harry Vinters, Jenaro Felix. Creutzfeldt-Jakob disease and other prion disorders. In: The Neuropsychiatry of Alzheimer's Disease and Related Dementias. CRC Press, 2003:243-253.

  213. 213

    Jeffrey Cummings, Harry Vinters, Jenaro Felix. Neurobiology of neuropsychiatric symptoms in dementias. In: The Neuropsychiatry of Alzheimer's Disease and Related Dementias. CRC Press, 2003:255-280.

  214. 214

    Andrew J Larner, Mark Doran. (2003) Prion diseases: update on therapeutic patents (1999 – 2002). Expert Opinion on Therapeutic Patents 13:1, 67-78

  215. 215

    Yue-Shan Piao, Koichi Wakabayashi, Akiyoshi Kakita, Mitsunori Yamada, Shintaro Hayashi, Takashi Morita, Fusahiro Ikuta, Kiyomitsu Oyanagi, Hitoshi Takahashi. (2003) Neuropathology with Clinical Correlations of Sporadic Amyotrophic Lateral Sclerosis: 102 Autopsy Cases Examined Between 1962 and 2000. Brain Pathology 13:1, 10-22

  216. 216

    A.J Modler, K Gast, G Lutsch, G Damaschun. (2003) Assembly of Amyloid Protofibrils via Critical Oligomers—A Novel Pathway of Amyloid Formation. Journal of Molecular Biology 325:1, 135-148

  217. 217

    J. Y. Richmond, R. H. Hill, R. S. Weyant, S. L. Nesby-O'Dell, P. E. Vinson. (2003) What's Hot in Animal Biosafety?. ILAR Journal 44:1, 20-27

  218. 218

    Csaba Söti, Péter Csermely. (2002) Chaperones and aging: role in neurodegeneration and in other civilizational diseases. Neurochemistry International 41:6, 383-389

  219. 219

    V Lewis, A Boyd, CL Masters, SJ Collins. (2002) Apparently sporadic CJD and covert health-care transmissions. The Lancet Neurology 1:8, 470-471

  220. 220

    Stephen J DeArmond, Essia Bouzamondo. (2002) Fundamentals of prion biology and diseases. Toxicology 181-182, 9-16

  221. 221

    Jorge Ghiso, Blas Frangione. (2002) Amyloidosis and Alzheimer’s disease. Advanced Drug Delivery Reviews 54:12, 1539-1551

  222. 222

    Arthur Horwich. (2002) Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions. Journal of Clinical Investigation 110:9, 1221-1232

  223. 223

    Arthur Horwich. (2002) Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions. Journal of Clinical Investigation 110:9, 1221-1232

  224. 224

    Arthur Horwich. (2002) Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions. Journal of Clinical Investigation 110:9, 1221-1232

  225. 225

    Josh P. Roberts. (2002) Prion vaccine: is there hope against CJD?. Drug Discovery Today 7:18, 936-937

  226. 226

    Einar M Sigurdsson, Thomas Wisniewski, Blas Frangione. (2002) Infectivity of amyloid diseases. Trends in Molecular Medicine 8:9, 411-413

  227. 227

    Marina D. Kirkitadze, Gal Bitan, David B. Teplow. (2002) Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies. Journal of Neuroscience Research 69:5, 567-577

  228. 228

    Norman M. Kaplan, Biff F. Palmer, Belinda A. Vicioso. (2002) Dementia:. The American Journal of the Medical Sciences 324:2, 84-95

  229. 229

    David J. Weber, William A. Rutala. (2002) Managing the risk of nosocomial transmission of prion diseases. Current Opinion in Infectious Diseases 15:4, 421-425

  230. 230

    Einar M. Sigurdsson, David R. Brown, Maki Daniels, Richard J. Kascsak, Regina Kascsak, Richard Carp, Harry C. Meeker, Blas Frangione, Thomas Wisniewski. (2002) Immunization Delays the Onset of Prion Disease in Mice. The American Journal of Pathology 161:1, 13-17

  231. 231

    Tamas Revesz, Janice L. Holton, Tammaryn Lashley, Gordon Plant, Agueda Rostagno, Jorge Ghiso, Blas Frangione. (2002) Sporadic and Familial Cerebral Amyloid Angiopathies. Brain Pathology 12:3, 343-357

  232. 232

    Carlos Morgan, Manuel P Bugueño, Jorge Garrido, Nibaldo C Inestrosa. (2002) Laminin affects polymerization, depolymerization and neurotoxicity of Aβ peptide. Peptides 23:7, 1229-1240

  233. 233

    Nobuyuki Sasaki, Masayoshi Takeuchi, Hiroshi Chowei, Seiji Kikuchi, Yorihide Hayashi, Norihito Nakano, Hiroshi Ikeda, Sho-ichi Yamagishi, Tetsuyuki Kitamoto, Toshikazu Saito, Zenji Makita. (2002) Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques.. Neuroscience Letters 326:2, 117-120

  234. 234

    J Hauw. (2002) Le destin du cerveau ? Un point de vue neuropathologique sur les démences.. Comptes Rendus Biologies 325:6, 655-664

  235. 235

    Richard T. Johnson. (2002) Risks of bovine spongiform encephalopathy and variant creutzfeldt-jakob disease in the United States. Current Neurology and Neuroscience Reports 2:2, 97-99

  236. 236

    Colin Blake. Prion. In: Encyclopedia of Molecular Biology. John Wiley & Sons, Inc., 2002.

  237. 237

    PD Griffiths. (2002) Preparing to treat prions. Reviews in Medical Virology 12:1, 1-3

  238. 238

    Antonio Guerrero Espejo. (2002) Las vacas locas y las enfermedades priónicas humanas. Enfermedades Infecciosas y Microbiología Clínica 20:4, 141-143

  239. 239

    Giampaolo Merlini, Vittorio Bellotti, Alessia Andreola, Giovanni Palladini, Laura Obici, Simona Casarini, Vittorio Perfetti. (2001) Protein Aggregation. Clinical Chemistry and Laboratory Medicine 39:11, 1065-1075

  240. 240

    Laurenson , Ian F. , Whyte , Andrew S. , Fox , Chris , . (2001) Iatrogenic Prion Infection. New England Journal of Medicine 345:11, 840-841
    Free Full Text

  241. 241

    Ramón Cacabelos. (2001) Psychogeriatric Research: A Conceptual Introduction to Aging and Geriatric Neuroscience. Psychogeriatrics 1:3, 158-188

  242. 242

    Roos , Raymond P. , . (2001) Controlling New Prion Diseases. New England Journal of Medicine 344:20, 1548-1551
    Full Text

Trends

Most Viewed (Last Week)

More Trends

Article Category
Research
Reviews
Clinical Cases
Perspective
Commentary
Other
Browse all articles
Multimedia
Videos in Clinical Medicine
Images in Clinical Medicine
Interactive Medical Cases
Weekly Audio Summaries
Browse all multimedia
This Week
Last Week
Browse full index
Selected Specialties
Cardiology
Endocrinology
Gastroenterology
Genetics
Hematology/Oncology
Infectious Disease
Nephrology
Neurology/Neurosurgery
Obstetrics/Gynecology
Pediatrics
Primary Care/Hospitalist
Pulmonary/Critical Care
Surgery
Browse all Specialties & Topics
Featured Topics
Clinical Practice Center
Health Policy and Reform
Medicine and Society
Global Health
Influenza A (H7N9)
Author Center
Submit a Manuscript or Letter
Track a Manuscript
Help